Podcasts about Mayo Clinic

Host: Darryl S. Chutka, M.D.  Guest: Stacey Rizza, M.D.  Lyme Disease is a tick-borne illness commonly seen in various parts of the country. Despite its common occurrence in the primary care practice, it's associated with confusion and controversy. From the presenting symptoms, occasional ambiguous serologic results, to managing patients with persistent symptoms following treatment, primary care clinicians are often frustrated with the management of patients who have or are concerned they have Lyme Disease. In today's podcast, we'll discuss what we know about Lyme Disease, what's still uncertain, and how we should approach this health problem in our patients. Joining me for this podcast is Dr. Stacey Rizza, an infectious disease specialist at the Mayo Clinic.  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development

A severe blockage in the "widowmaker" artery sounds like an automatic trip to the cath lab but is it always? In this episode, Dr. Robert Todd Hurst, MD, FACC, FASE shares a remarkable real-world case that challenges conventional thinking about stents and heart disease treatment. He explains the difference between stable and unstable coronary artery disease, reviews the research behind stents versus aggressive medical therapy, and reveals how one patient with a severe LAD blockage improved his artery health without undergoing an invasive procedure. You'll also learn why understanding root causes, optimizing risk factors, and taking a personalized approach to prevention may be more important than many people realize. About Dr. Robert Todd Hurst, MD, FACC, FASE Dr. Robert Todd Hurst, MD, FACC, FASE is a board-certified preventive cardiologist, former Mayo Clinic physician, and founder of HealthspanMD. His mission is simple: that no one dies of a heart attack, ever. Through a proactive, precision-medicine approach, he helps patients identify hidden cardiovascular risk, reverse heart disease, and add strong, vital, mentally sharp years to life. In this podcast, he shares practical insights from more than two decades of experience helping people prevent and overcome cardiovascular disease. Key Timestamps 00:00 – Introduction: Do severe blockages always require a stent? 00:27 – Case study: A patient with a severe LAD ("widowmaker") blockage and no symptoms 01:14 – Why stress testing, echocardiograms, and symptoms matter when evaluating blockages 01:39 – What research shows about stents versus aggressive medical therapy for stable coronary artery disease 02:46 – The real risks of angiograms, stents, and invasive procedures 03:36 – Why the patient's condition did not automatically justify a stent 04:15 – Optimizing cholesterol, insulin resistance, and other root causes 04:42 – One year later: Severe blockage improves to moderate stenosis 05:04 – Evidence of plaque regression and why the results matter 05:35 – How cardiology thinking has evolved since the COURAGE trial 06:07 – When stents and bypass surgery may still be the right choice 06:41 – Questions every patient should ask before agreeing to a stent 07:02 – Long-term considerations and risks of living with a stent 07:20 – Why healthcare remains reactive instead of preventive 07:47 – HealthspanMD's mission: Moving from disease treatment to health optimization 08:08 – Final thoughts and invitation to learn more about HealthspanMD 08:34 – Medical disclaimer This episode is for educational purposes only and should not be considered medical advice. Always discuss treatment decisions with your healthcare provider. This information is for educational purposes only and is not medical advice. Don't make any decisions about your medical treatment without first talking to your doctor. Connect* with HealthspanMD :

Send us Fan MailCommon questions about fasting Most common questions•What is intermittent fasting?•What is the best fasting schedule, like 16:8 or 5:2?•Can it help with weight loss?•What am I allowed to drink during the fasting window?•Will it hurt energy, focus, or workouts?•Is it safe for everyone?•Does it matter what I eat when I do eat?•How long does it take to see results?•Can I do it every day?•What are the side effects or risks?What people worry about most:  A lot of the concern is about whether fasting is actually healthy, whether the benefits last, and whether it is just another calorie-cutting strategy in disguise. Mayo Clinic notes that some short-term improvements have been seen in blood sugar, weight, cholesterol, blood pressure, and inflammation, but long-term effects are still unclear. MedlinePlus also highlights that what and how much you eat still matter, not just the timing

The Central Role of Cardiac MRI in the Management of Heart Failure and Cardiomyopathy Patients   Guest: Gosia Wamil, M.D., Ph.D. Host: Malcolm R. Bell, M.D.   Cardiac MRI is now central to heart failure care, moving beyond imaging to guide diagnosis and treatment. It distinguishes disease causes, identifies fibrosis and scar, and uncovers specific conditions in both HFrEF and HFpEF. By providing prognostic markers, it helps tailor therapies and improve outcomes—delivering the right treatment at the right time. In this episode of "Interviews With the Experts," Dr. Malcolm Bell interviews Dr. Gosia Wamil from Mayo Clinic London practice on the role of cardiac MRI in practice.   Topics Discussed: When does CMR change the management decision? CMR findings Which CMR biomarkers truly predict outcomes—and how should clinicians act on them? From echo-first to CMR-led pathways: what should every HF service implement now?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode.   Podcast episode transcript found here.   Recorded on: 14-January-2026  

Myoscience Creatine with 20% off: https://bit.ly/43EWGRc   Pre-order Keto Flex Revised and get free bonuses at: https://bit.ly/4wKG1sM    I'm 41 and I Feel Younger Than I Did at 25. The 5 Exercises Behind It. People who can lower themselves to the floor and stand back up cleanly have a roughly 3 to 4% risk of dying in a given follow-up period. People who struggle? 42%. That's the kind of longevity signal no blood test or gadget can match, and you can run it in your living room in 10 seconds. In this episode, I share the five exercises that have helped me feel genuinely younger at 41 than I did at 25. Not because of genetics or living in the gym, but because I stopped letting critical movements disappear. Each one targets a specific ability that fades first: energy, mobility, strength, power, and the single movement that predicts long-term independence. I also share the Mayo Clinic study on mitochondria and HIIT that showed older bodies responding more than younger ones to training, why power declines almost twice as fast as strength after 40, and the personal moment with my German Shepherd Ziggy that forced me to take hip hinge strength seriously. Key Takeaways: Most people don't get old first. They get weak first. Accelerated aging is driven by the movements you stop practicing. Mayo Clinic research showed older adults boosted cellular energy capacity by 69% on HIIT, compared to 49% in younger adults. Power (force produced quickly) fades nearly twice as fast as strength after 40, and people with low power have nearly 6x the risk of dying. The sit-to-stand floor test separates a 3 to 4% mortality risk from a 42% one. It tests everything, leg strength, mobility, balance, and coordination, in one movement. Single-leg balance for 10 seconds is one of the most sensitive aging signals available and almost nobody is checking it. After age 30, natural creatine production declines, making recovery, strength, and brain function harder to maintain without supplementation. Find All The Ben Azadi Show Sponsorship Deals ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.ketokamp.com/sponsorship-deals Learn more about your ad choices. Visit megaphone.fm/adchoices

You could be eating well, supplementing intentionally, and doing all the "right" things and still be quietly working against yourself every single day. Not because of what you're not doing, but because of what you're putting in and on your body without realizing it. Nobody told us either, until someone who loved us did. Now we're telling you.This episode is a swap episode. Six things, three from Brandi and three from Dr. Desiree, that we have personally changed in our own lives. Not from a place of panic, but from a place of having the information and making the obvious next move. The science on what's in conventional cookware, makeup, lotion, and coffee isn't obscure. The product industry just hasn't had much incentive to share it. We do.Brandi walks through her swaps from body butter to wooden kitchen utensils to a blood-sugar-stable chocolate bar that actually tastes like a chocolate bar. Dr. Desiree covers the research on non-stick cookware and forever chemicals, the fragrance loophole hiding in your makeup bag, and what's really in most commercial coffee. None of these swaps require blowing up your life. Most of them cost the same or less than what you're already using.What You'll Learn:Why the first ingredient on most conventional lotions is water and what that means for your skin barrierWhat Chaga's ORAC value actually is and why applying antioxidants topically to inflamed or psoriatic skin has a real mechanism behind itWhat happens when a plastic or silicone spatula sits in a hot pan (and why "BPA-free" didn't solve the problem)Why monk fruit has a glycemic index of zero and how that changes what happens to your energy an hour after a sweet snackThe PFAS "forever chemicals" in conventional non-stick cookware, what temperature matters, and the simple technique that makes stainless steel actually workThe fragrance loophole in US and Canadian cosmetic labeling that lets one word hide dozens to hundreds of undisclosed compoundsWhy coffee is one of the most heavily pesticide-sprayed crops in the world and how mycotoxins get in before the bag ever reaches your kitchenHow L-theanine in matcha changes the quality of caffeine in the body and why it may matter more for perimenopausal women managing cortisolFour free apps and databases you can use right now to check what's actually in your makeup before you repurchase itResources Mentioned:EWG Skin Deep database (free ingredient safety ratings): https://www.ewg.org/skindeep/Yuka app (scan product barcodes in-store for ingredient scores): https://yuka.io/en/SkinSafe (developed with Mayo Clinic, helpful for sensitive skin): https://www.skinsafe.com/Merit makeup: https://www.meritbeauty.com/Your Next Steps:Follow us on Instagram: https://www.instagram.com/eversiowellness/Shop Eversio Wellness and save 15% with code PODCAST15: https://www.eversiowellness.com/discount/PODCAST15?redirect=%2Fcollections%2Fall-productsNot sure which mushroom is right for you? Take our free quiz: https://www.eversiowellness.com/pages/take-our-quiz

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss updates on the Protecting Access to Medicare Act (PAMA) and other policy changes affecting clinical diagnostics. Later, Dr. Pritt welcomes Ann Moyer, M.D., Ph.D., a molecular genetic pathologist at Mayo Clinic and chair of the hereditary genetics practice, to explore how precision therapeutics are improving cancer treatments.PAMA update (00:01): Get the latest on PAMA as the first data collection period begins, including ongoing efforts to advance the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.Policy changes influencing diagnostics (04:09): Learn how evolving reimbursement policies for blood-based cancer screening and a proposed CLIA modernization bill may impact the field.Pharmacogenomic tests improving cancer care (08:14): Discover how pharmacogenomics are benefiting patients with cancer, the benefits of medication-based testing, and how this field is advancing.ResourcesCMS: CLFS & PAMA reporting and resourcesPrecision Oncology Therapeutics: Personalized cancer treatmentAnswers From the Lab: Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.Answers From the Lab: Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

Award-winning journalist Lindsey Seavert is our new host as we explore the innovations changing the landscape of medicine. Featuring conversations with leading physicians, researchers, and medical experts, the new season looks at everything from AI-powered diagnostics and cutting-edge cancer therapies to surgical technologies improving patient care today.Across a new series of in-depth conversations, we explore the breakthroughs that rarely make headlines and the ways medicine continues to evolve. Becoming smarter, more human, and more connected. Whether you are a patient, clinician, or simply curious about where medicine is headed next, Tomorrow's Cure delivers accessible, thought-provoking insights wherever you listen to podcasts.How to listen and stay connected:Subscribe to Tomorrow's Cure on your favorite podcast app and follow the show so you never miss an episode. Get the latest health information from Mayo Clinic's experts—subscribe to Mayo Clinic's newsletter for free today: https://mayocl.in/3EcNPNc Connect with Mayo Clinic: Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/ Follow Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/ Follow Mayo Clinic on X (formerly Twitter): https://x.com/MayoClinic Follow Mayo Clinic on Threads: https://www.threads.net/@mayoclinic

You built something successful. Maybe it's a course that sells. Maybe it's a coaching program. Maybe you're the expert on the speaking circuit. You're established. You're making good money. People know who you are. And something feels off. In this episode of The Expert Edge, I sit down with Dr. Larry Daugherty, a radiation oncologist who went from living his "dream career" at Mayo Clinic to realizing he was hollow inside. He made the radical pivot into his actual passion, monetized before it was perfect, and built a thriving community-based business that fulfills him. This conversation is for the established expert who's wondering if there's more to the game. Why your courses aren't selling like they used to. Why community beats information. And how to build a business around what actually matters to you. What you'll learn: → Monetize first, perfect later - Why action beats analysis every time (especially when you're already established) → Higher ticket clients are fundamentally different - The 6X difference in results when you serve premium clients who show up with commitment → Small cohorts demand ruthless selection - Why one person not taking action in a five-person group spreads like a disease (but goes unnoticed in larger groups) → Community is your moat now - Why information is commoditized and belonging is the new currency → The suppressed part of yourself - How successful experts often realize they've buried the part that actually comes alive Real insights from the episode: Larry's story: from Mayo Clinic dream job to feeling hollow inside despite everything he worked for The moment an advertisement for a dog sled race above the Arctic Circle changed his entire trajectory Why he pivoted from courses to building a premium community-based business How he went from $3.5K to $5K to $30K offerings by monetizing before perfecting Why higher ticket clients are easier to work with (and produce 6X better results) The mistake of filling seats instead of selecting carefully in small cohorts How AI has made courses commoditized (and what to do about it) The shift from selling information to selling belonging and community Why the highest level of success requires authenticity and vulnerability   If you're an established coach, consultant, speaker, or course creator who's wondering if there's more to this game, Larry's story is for you. He went from a six-figure career to pivoting into community-based business that actually fulfills him. Check out his work at thefreedomphysician.com to see how he applied these principles. The frameworks work across industries: monetize first, build community, and scale through belonging instead of information. Join our next Speak to Convert Masterclass. In this live workshop, you'll discover how to build and launch a high converting presentation that gets you clients every time you present. https://colinboyd.co/speak Discover how to authentically connect with your audience & fill your programs with a Conversion Story - Version 2.0 (AI Edition) is now available. https://www.conversionstoryformula.com Hit the "Follow" button so you don't miss an episode! Love this podcast? Write a review and give it a 5-star rating!  For all the show notes and links: https://www.expertedgepodcast.com/blog/episode324 Connect with Colin on Instagram: https://www.instagram.com/colinboyd/  

Host: Darryl S. Chutka, M.D.  Guest: Stacey Rizza, M.D.  We've now had our second outbreak of a potentially deadly infectious disease. Hantavirus has been diagnosed in several individuals and most recently just under 100 cases of Ebola Virus have been confirmed along with several hundred suspected cases. Ebola virus is caused by several species of the Ebola Virus and is frequently fatal.  Early symptoms are non-specific and similar to other common viral infections, making an early diagnosis challenging. Who's at risk of acquiring Ebola Virus? How is it spread from person to person? How deadly is the virus and finally, does it have the potential to become our next pandemic?  In this podcast, we're going to learn more about Ebola Virus. My guest is an infectious disease specialist, Dr. Stacey Rizza from the Mayo Clinic.  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

Anthropic is preparing for public markets. Europe is pushing to reduce its reliance on American tech. And CNN just filed a copyright lawsuit against Perplexity. This week, Anthropic files confidential paperwork for an IPO in one of the biggest milestones yet for the AI industry, Europe unveils a tech sovereignty plan to reduce its dependence on American technology, CNN sues Perplexity over the alleged redistribution of more than 17,000 copyrighted stories, Morgan Stanley opens its platform to external AI agents using MCP, and Microsoft teams up with Mayo Clinic to build an AI model for healthcare. If you are a founder, operator or executive trying to keep up with AI, this is your weekly five minute briefing. Stories Covered This Week: Anthropic files confidential paperwork for an IPO, with OpenAI expected to follow soon Europe unveils a tech sovereignty plan to build out data centers, revive its chip industry and buy more from European suppliers CNN sues Perplexity over the alleged use of more than 17,000 copyrighted stories, photos and videos Morgan Stanley becomes one of the first major Wall Street banks to open its platform to external AI agents via MCP Microsoft and Mayo Clinic partner to build an AI model designed specifically for healthcare Episode Timestamps: 00:00 Intro 00:17 Anthropic files to go public 01:17 Europe pushes for tech sovereignty 02:28 CNN sues Perplexity 03:23 Morgan Stanley opens up to AI agents 04:22 Microsoft and Mayo Clinic build a healthcare AI 05:11 Outro Partner Links: Upgrade your AI toolkit: https://www.theaireport.ai/ai-executive-pass Subscribe to our free newsletter: https://newsletter.theaireport.ai/subscribe Join the community: https://community.theaireport.ai/checkout/the-ai-report-welcome-gift?coupon_code=WRTH Learn more about your ad choices. Visit megaphone.fm/adchoices

AI in Imaging: How Will it Change What We Do   Guest: Tim Poterucha, M.D. Host: Kyle Klarich, M.D.   Artificial intelligence (AI) is beginning to reshape how we acquire, interpret, and act on cardiovascular imaging, particularly echocardiography. In this episode, we'll walk through how we got here—from the historical innovation arc of echo to modern AI tools that segment images, detect disease, and support interpretation—and discuss what is real, what is hype, and where the true clinical opportunities and risks lie. We'll also explore what this means for practicing clinicians and trainees who are considering a future in imaging.   Topics Discussed: When it comes specifically to cardiovascular imaging, what is the current role of AI, and why is imaging such a natural fit for these tools? What are the problems with how we interpret imaging now, and what are the risks of AI? What is hype right now, and what is real? Is AI going to replace cardiologists for medical imaging interpretation, and should cardiology fellows be worried about going into imaging with the rise of AI?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode.   Podcast episode transcript found here.   Recorded 01-December-2025

Duct fixes a lot of things, including my comedy career. Ok, not really my career, but the transportation getting me to the gigs. Here's a quick, embarrassing story about my use of duct tape. Not really looking my best as I drove around the country, but it ws functional . . .for a while.  https://www.TheWorkLady.com  Jan McInnis is a top change management keynote speaker, comedian, and funny motivational speaker who helps organizations use humor to handle change, build resilience, and strengthen leadership skills. With her laugh-out-loud stories and practical tips, Jan shows audiences how humor isn't just entertainment—it's a business skill that drives communication, connection, and stress relief. A conference keynote speaker, Master of Ceremonies, and comedy writer, Jan has written material for The Tonight Show with Jay Leno as well as radio, TV, and syndicated cartoon strips. She's the author of two books—Finding the Funny Fast and Convention Comedian—and her insights on humor in business have been featured in The Wall Street Journal, The Washington Post, and The Huffington Post. For over 25 years, she has been helping leaders and teams discover how to bounce back from setbacks, embrace change, and connect through comedy. Jan has delivered keynote speeches at thousands of events nationwide, from the Federal Reserve Banks to the Mayo Clinic, for industries that include healthcare, finance, government, education, women's leadership events, technology, and safety & disaster management. Her client list features respected organizations such as: Healthcare: Mayo Clinic, Kaiser Permanente, Abbott Pharmaceuticals, Health Information Management Associations, Assisted Living Associations Finance: Federal Reserve Banks, Merrill Lynch, Transamerica Insurance, BDO Accounting, American Institute of CPAs, credit unions, banking associations Government: U.S. Air Force, Social Security Administration, International Institute of Municipal Clerks, National League of Cities, public utilities, correctional associations Women's Leadership Events: Toyota Women's Conference, Go Red for Women, Speaking of Women's Health, Soroptimists, Women in Insurance & Financial Services Education: State superintendent associations, community college associations, Head Start associations, National Association of Elementary and Middle School Principals Safety & Disaster: International Association of Emergency Managers, Disney Emergency Management, Mid-Atlantic Safety Conference, risk management associations   Her background as a Washington, D.C. marketing executive gives her a unique perspective that blends business acumen with stand-up comedy. Jan was also honored with the Greater Washington Society of Association Executives "Excellence in Education" Award. Along with her podcast Finding the Funny: Leadership Tips from a Comedian, Jan also produces Comedian Stories: Tales From the Road in Under 5 Minutes. Whether she's headlining a major convention, hosting a leadership retreat, or teaching resilience at a safety conference, Jan's programs give audiences the tools to laugh, learn, and lead.  

Get Myoscience Creatine and Magnesium (20% off) HERE: https://bit.ly/4ocjMbp  Pre-order Keto Flex Revised and get free bonuses: https://bit.ly/4wKG1sM    Men today are walking around with 20 to 30% less testosterone than their fathers had at the exact same age. Not because of disease. Because of five everyday habits that modern men think are completely normal. In this episode, I'm breaking down the five silent mistakes that are aging men faster than anything else right now, the science behind why they're so damaging, and the exact daily stack I personally use to fight back. I'm 41 years old and I've watched this happen to men I love. The decline doesn't announce itself. But it can be reversed. Key Takeaways: Men today have 20 to 30% less testosterone than men of the same age in 1988, per the Massachusetts Male Aging Study Grip strength predicts death more accurately than blood pressure, per a Lancet meta-analysis of 140,000 people One week of sleeping 5 hours or less drops testosterone by 10 to 15%, the equivalent of aging 10 to 15 years Sitting for long hours thins the memory center of the brain, and exercise does not offset this damage 85-year-olds gained muscle and reversed fiber-level aging in 12 weeks of resistance training in a Mayo Clinic study The five mistakes: stopping explosive movement, stopping brain challenges, ignoring muscle decline, neglecting recovery, and accepting decline as normal The simple daily stack: outdoor walks, heavy lifting twice a week, one gram of protein per pound of ideal body weight, 7+ hours of sleep, creatine, magnesium, and weekly brain challenges Find All The Ben Azadi Show Sponsorship Deals ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.ketokamp.com/sponsorship-deals Learn more about your ad choices. Visit megaphone.fm/adchoices

Moderator: Cat Burkat, MD FACS (Professor at Univ of Wisconsin-Madison) Guests · Dr. Elizabeth Bradley, Associate Professor at the Mayo Clinic, Rochester · Dr. François Codère Associate Professor from the Université de Montréal in Canada · Dr. Richard Allen, Professor at Baylor in Texas   In this Surgical Spotlight TOP podcast episode: "Myogenic Ptosis: Is It Really Any Different?", we are diving into a topic that most oculoplastic surgeons encounter—but rarely explore in depth: the surgical management of myogenic ptosis in progressive conditions such as Oculopharyngeal Muscular Dystrophy and Chronic Progressive External Ophthalmoplegia. We'll explore how the natural history of myogenic ptosis may change surgical decision-making. Should timing and the selected procedure be driven not just by the exam—but by disease trajectory? Does earlier onset signal a more aggressive course, pushing us toward more proactive surgery rather than a traditional stepwise approach? And how should we rethink concepts like recurrence, failure, and even surgical success when progression is expected? Tune in as we discuss the challenge of correcting myogenic ptosis—for today, and where the patient will be years from now.

If you're on a GLP-1 and nobody told you how to eat on it, this one's for you. We get into it in depth.Andrea Donsky, nutritionist, bestselling author of Nourishing Menopause, 7x published menopause researcher, menopause educator, and co-founder of wearemorphus.com, sits down with nutrition and fitness coach Natalie Bean, who is GLP-1 certified and has spent 31 years helping people change how they eat. If you're taking Ozempic, Mounjaro, or Wegovy, thinking about it, or you just want to take back control with food, Natalie walks through what actually protects your body. Spoiler: protein is not optional, and the scale is not the whole story.What you'll learn:Why a GLP-1 can cost you 25 to 40 percent of your weight as muscle, and how to push back with foodHow much protein women in perimenopause and menopause really need (and why it climbs on a GLP-1)Whether you'll gain the weight back when you stop, and what a maintenance dose actually doesThe GLP-1 side effects nobody warns you about, from dry mouth to constipation to brittle bonesWhy cardio is not the enemy, and where strength training and cortisol fit inChapters0:00 GLP-1 and muscle loss: the Mayo Clinic stat that stopped me0:48 Meet Natalie Bean and who GLP-1 meds are really for4:45 Food noise, sugar cravings, and insulin resistance after 409:45 Do you gain the weight back after stopping a GLP-1?14:10 How much protein you actually need on a GLP-119:40 GLP-1 side effects: dry mouth, digestion, bones, dehydration25:10 Fiber, constipation, and eating every 2 to 3 hours30:10 Why consistency beats variety when you start over35:10 Cortisol, cardio vs strength, and non-negotiable supplementsListen to this next:Tired of Fighting Food Cravings? Try This Instead: https://youtu.be/2PQxAbnll8sWork with Natalie: https://nutritionforeverinc.com/Send us Fan Mail ======Morphus: Menopause Reimagined

Everybody has advice, but you better not listen to all of it. There is a LOT of bad advice out there; especially when it comes to comedy and entertainment. I've had lots of people give me advice, but I've only taken a little of it. Here's a quick story about some really bad advice. It's also kinda funny. But it truly is not something I took seriously. https://www.TheWorkLady.com  Jan McInnis is a top change management keynote speaker, comedian, and funny motivational speaker who helps organizations use humor to handle change, build resilience, and strengthen leadership skills. With her laugh-out-loud stories and practical tips, Jan shows audiences how humor isn't just entertainment—it's a business skill that drives communication, connection, and stress relief.   A conference keynote speaker, Master of Ceremonies, and comedy writer, Jan has written material for The Tonight Show with Jay Leno as well as radio, TV, and syndicated cartoon strips. She's the author of two books—Finding the Funny Fast and Convention Comedian—and her insights on humor in business have been featured in The Wall Street Journal, The Washington Post, and The Huffington Post. For over 25 years, she has been helping leaders and teams discover how to bounce back from setbacks, embrace change, and connect through comedy.   Jan has delivered keynote speeches at thousands of events nationwide, from the Federal Reserve Banks to the Mayo Clinic, for industries that include healthcare, finance, government, education, women's leadership events, technology, and safety & disaster management. Her client list features respected organizations such as: Healthcare: Mayo Clinic, Kaiser Permanente, Abbott Pharmaceuticals, Health Information Management Associations, Assisted Living Associations Finance: Federal Reserve Banks, Merrill Lynch, Transamerica Insurance, BDO Accounting, American Institute of CPAs, credit unions, banking associations Government: U.S. Air Force, Social Security Administration, International Institute of Municipal Clerks, National League of Cities, public utilities, correctional associations Women's Leadership Events: Toyota Women's Conference, Go Red for Women, Speaking of Women's Health, Soroptimists, Women in Insurance & Financial Services Education: State superintendent associations, community college associations, Head Start associations, National Association of Elementary and Middle School Principals Safety & Disaster: International Association of Emergency Managers, Disney Emergency Management, Mid-Atlantic Safety Conference, risk management associations   Her background as a Washington, D.C. marketing executive gives her a unique perspective that blends business acumen with stand-up comedy. Jan was also honored with the Greater Washington Society of Association Executives "Excellence in Education" Award. Along with her podcast Finding the Funny: Leadership Tips from a Comedian, Jan also produces Comedian Stories: Tales From the Road in Under 5 Minutes. Whether she's headlining a major convention, hosting a leadership retreat, or teaching resilience at a safety conference, Jan's programs give audiences the tools to laugh, learn, and lead.  

In this episode of the Brain & Life Podcast, co-host Dr. Katy Peters is joined by novelist and disability advocate Sabina Nordqvist. Sabina discusses her personal 12-year battle with idiopathic intracranial hypertension (IIH), POTS, and Ehlers-Danlos syndrome. She shares the profound impact of misdiagnosis, the importance of self-advocacy, and how her experiences in support groups led her to write a novel called It's All in Your Head that puts disabled characters front and center. Dr. Peters is then joined by Dr. Jeremy Cutsforth-Gregory, an Assistant Professor of Neurology at Mayo Clinic in Rochester, Minnesota, working in the Division of Neurologic Education. Dr. Cutsforth-Gregory explains cerebrospinal fluid and IIH, highlighting the treatments that are available and where research is going next.   Additional Resources Sabina Nordqvist- It's All in Your Head Understanding the Mysteries of POTS and Other Autonomic Disorders A Swimmer Returns to the Pool After Ehlers-Danlos Syndrome Diagnosis   Brain & Life Podcast Episodes on Similar Topics Parenting and Writing While Disabled with Jessica Slice Outdoors Woman Crystal Gail Welcome on Nature and Chronic Pain Author Samantha Lee Schmall on Life Beyond the Shunt   We want to hear from you! Have a question or want to hear a topic featured on the Brain & Life Podcast? ·       Record a voicemail at 612-928-6206 ·       Email us at BLpodcast@brainandlife.org   Social Media Guests: Sabina Nordqvist @nordqvistbooks; Dr. Cutsforth-Gregory @mayoclinic Hosts: Dr. Daniel Correa @neurodrcorrea; Dr. Katy Peters @KatyPetersMDPhD

Developed by the AUA Residents and Fellows Committee, each episode of the Training Transformed podcast series features an interview with a urology faculty member and resident physician surrounding an innovative facet of resident education at their institution. Tune in for our sixth episode as moderator, Dr. Kayla Graham, chats with Dr. Abhinav Khanna and Dr. Britney Honda about the surgical video review program at the Mayo Clinic Department of Urology in Rochester, Minnesota.

Losing weight on Ozempic, Wegovy, or Mounjaro but feeling bloated, constipated, and miserable? There's a reason, and a new Mayo Clinic study finally proves it.76% of patients on GLP-1s tested positive for SIBO. 91% had methane overgrowth. Dr. Kenneth Brown breaks down why these drugs turn your small intestine into a swamp, why your microbiome decides if the drug even works, and the exact protocol to fix it without quitting the medication.If you're on a GLP-1 or thinking about it, watch this first.

In this episode, Lyell K. Jones Jr, MD, FAAN, speaks with Cheryl Bushnell, MD, MHS, who served as the guest editor of the June 2026 Cerebrovascular Disease issue. They provide a preview of the issue, which publishes on June 3, 2026. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Bushnell is a Professor of Neurology and Director of the Center for Transformative Stroke Care at Wake Forest University School of Medicine in Winston-Salem, North Carolina. Additional Resources Read the issue: continuum.aan.com Subscribe to Continuum®: shop.lww.com/Continuum Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Guest: @CBushnellMD  Full episode transcript available here Dr Jones: One of the core tenets of our field is that we learn neurology one stroke at a time. But what do we have to learn about preventing them altogether? The science of stroke prevention, acute treatment, and recovery are evolving rapidly, and it's hard to keep up. Today, we're speaking with Dr. Cheryl Bushnell, guest editor of our latest Continuum issue on Cerebrovascular Disease, to discuss these topics and much more.  Dr Jones: This is Dr. Lyell Jones, editor-in-chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about subscribing to the journal, listening to verbatim recordings of the articles, and exclusive access to interviews not featured on the podcast.  Dr Jones: This is Dr. Lyell Jones, editor-in-chief of Continuum: Lifelong Learning in Neurology. Today, I'm interviewing Dr. Cheryl Bushnell, who is Continuum's guest editor for our latest issue on Cerebrovascular Disease. Dr. Bushnell is a professor of neurology and the director of the Center for Transformative Stroke Care at the Wake Forest University School of Medicine in Winston-Salem, North Carolina, where she specializes in the care of stroke patients and their social and functional determinants of recovery and health, and is an internationally recognized expert on those topics. Dr. Bushnell, welcome. Thank you for joining us today. Why don't you introduce yourself to our listeners?  Dr Bushnell: Absolutely. Thank you for the invitation. It's really an honor to be here. So, as you mentioned, I am the director of the Center for Transformative Stroke Care at Wake Forest. It's a really fun transition for me to be involved with different care models for stroke, and I think a lot of the Continuum topics are directly relevant to some of the things that I'm doing now as an administrator and sort of a facilitator of new research. So, thanks again for having me.  Dr Jones: Yeah, and, and you have a wonderful perspective, and we're gonna pull that out today in our interview questions, and I'm looking forward to sharing that with our listeners. But before we get to the questions, we're gonna start off today's podcast with another Continuum Audio trivia question for our listeners. Anticoagulation has played a critical role in secondary ischemic stroke prevention for a long time now. While direct oral anticoagulants have taken on a greater role in the treatment of prevention of stroke, there are still some use cases for vitamin K antagonists like warfarin. The trivia question for our listeners is this: How was warfarin discovered, and how did it get its name? Stick around and we'll share the answer to that question toward the end of our interview today. So, Dr. Bushnell, let's get right to it. You alluded to your various roles, and your leadership in the field has been exemplary. The interventions for acute ischemic stroke have really exploded over the last decade or so, and they get a lot of attention and discussion, but prevention and recovery are just as important in the care of these patients. Tell us a little more about how you approached this issue, about the article topics you chose, etc.  Dr Bushnell: Well, once I was chosen to lead the guest editorship, I wanted to come up with a group of topics that were maybe a little bit different from previous issues. So, I kind of looked at the previous issues and saw, as you said, an emphasis on acute stroke, and that's really important because it has been evolving. But my thought was, how about what happens to patients after they get the intervention and they're discharged home? And because a lot of trainees may not get to see these patients ever again, or it's months before they might see them, or if they're readmitted, which is what we don't want to see, but that certainly is a lot of the exposure is in the inpatient setting. So, I thought I would kind of transport the education into the outpatient and transitional setting, as well as prevention, not only secondary, but primary prevention, with an emphasis on brain health. Some of the populations that may not get as much attention. So, sex differences, stroke in women, pregnancy, the transitions of care, and also the emphasis on holistic view of patients and their challenges, which includes the non-medical factors that drive health, otherwise known as social determinants of health.  Dr Jones: I appreciate that perspective, and obviously th-this is an area of your deep expertise, and it's great to have an issue that really digs into some of those topics a little more deeply. As an educator, I'm really glad you mentioned that about the trainee's perspective. You know, especially junior neurology trainees that are in the hospital all the time. They're seeing patients in the middle of a cerebrovascular catastrophe. But there's a long tail of recovery, right? And they'll get to see that in continuity clinic, but it's a good message to share from an evidence and, um, experiential perspective in the issue. So, appreciate that perspective. You've just read all these articles and edited them. Was there anything that you ran across that was a surprise to you?  Dr Bushnell: Well, I personally chose a lot of the authors based on my knowledge of their work. So, I wouldn't say that it was completely surprising, but I do think that I was just genuinely impressed with the quality of the writing and the synthesis of information. I just was incredibly proud of the work that these co-authors have put together. I'd say that that was-- it wasn't surprising so much as just a sense of pride that I had with the product that's coming out. But of course, there have been some new trials that had to be incorporated at the last minute, some of which were presented at the International Stroke Conference just a few weeks ago.  Dr Jones: Yeah. We try to be as up-to-date as we can, and I will completely agree with you. We have some really good writers in our field, and it's really just a pleasure when you read an article that's by an expert, and it's a joy to read. I can tell you it's one of the best parts of this job, and you get to learn a lot. I think one of the more challenging scenarios that I hear about from colleagues in recent years has been optimal management of patients with asymptomatic extracranial atherosclerosis. The pivotal trials that inform how we manage those patients were from a long time ago, decades ago, predating a lot of the more intensive medical management tools that we have today. In that scenario, Dr. Bushnell, what's the latest on that, and what should our listeners know?  Dr Bushnell: Well, obviously, the CREST 2 trial has been long awaited. It's been going on for over ten years, I believe. Of course, it's, uh, two different trials all in one, the carotid stenting and angioplasty versus intensive medical management. And of course, each of the carotid vascularization arms of the trial also had intensive medical management. And then the other trial is the carotid endarterectomy as the form of revascularization. And it interestingly did not show any benefit of carotid endarterectomy compared to intensive medical management. But of course, the somewhat surprising result was that carotid angioplasty and stenting truly was superior, although it was a small number of events in the trial overall. But that stenting plus intensive medical management was somewhat better than intensive medical management alone. And I think stenting has come a long way in terms of safety, and so I think that's been part of the evolution of the field. I do wanna say that I'm a huge fan of the intensive medical management, and I think that what the protocol does in terms of blood pressure management, cholesterol management is very much above and beyond what's done in private practice even. And the health coaching for all the other things related to diabetes and weight loss and smoking cessation and physical activity, that is what we need to be doing to actually decrease the risk of stroke, and I think that it's very effective. I can't say enough about the design of the study for that reason, that everyone gets the intensive medical management, and then you just layer on the type of revascularization on top of it. So, I wouldn't have been surprised if this was a completely negative trial overall. They just happened to have some better outcomes in the stenting arm.  Dr Jones: I recall a few years ago when the series of endovascular therapy trials for acute stroke came out, and I think there was a, a period of time where the field had to adapt to that. I wonder what you think about with the CREST 2 findings on stenting. I mean, is that gonna be a big change? Because obviously atherosclerosis is highly prevalent. Is that gonna be a big change? Is the field ready for that? How much adjustment do we have in store?  Dr Bushnell: I'm not sure it's gonna be a really big change. If you read the editorial that accompanied the trial in the New England Journal, just a few patients in either direction would have changed the outcome. I kind of look at it as an absolute difference that's relatively small. So, I'm not sure that it will have a huge impact on the field. I do think that the specialists who insert the stents may have some differences of opinion of who should be stented and who shouldn't. Because I think, you know, all of the specialists who do procedures were involved with the trial. But I would say there's a larger percentage of vascular surgeons who were involved, and so I'd say they may have a change of their practice. And neurologists may not even get involved at all.  Dr Jones: Right.  Dr Bushnell: That was one of the challenges for getting patients in the trial is that, you know, not all of us see the asymptomatic carotid stenosis, that they tend to get referred to vascular surgery. So, I think maybe in a corner of the practices of vascular surgeons is where you might see the differences.  Dr Jones: Your point about the way the trial was designed or the trials were designed, that intensive medical management is really important, and we have huge gaps in that. In our specialty, it's, you know, we have probably an opportunity in primary care even to address that. And that leads me to my next question. You know, given your perspective and your expertise, what do you think is the biggest practice gap in the care of patients with stroke or with cerebrovascular disease of any kind?  Dr Bushnell: I think by far the biggest gap is transitions of care and access to follow-up in a specialty clinic after discharge and continuous secondary prevention. We only call it secondary prevention because it happened to come after a stroke, but I really feel like we should just focus on prevention and call it that. There are a lot of people who are trying to kind of, get us away from primary versus secondary prevention. And, and Mitch Elkind is phenomenal and had a beautiful chapter weaving in prevention and brain health. So, I highly recommend that people, if they don't read any other chapters of the Continuum to read his, because I think that it's getting to your point about where the gaps are, and I think prevention is the biggest one. I think we could do so much more in models of care to ensure that there is a pathway once patients are discharged. We have no quality metrics. We have no measurement of how well people are doing after they're discharged. We have all of these fancy things and sophisticated acute treatments, but all of those are for naught if somebody goes home and they fall and they have a severe head injury or hip fracture because they weren't properly supervised or they didn't have the help that they needed at home. So, you got me on my soapbox here for a second, but that is definitely what I see as the gap.  Dr Jones: That's an important soapbox, an important gap, and obviously, if it was a simple problem, we could solve it. But it's obviously something that education is a valuable tool for that, and that's part of why we are including so much content in this issue of Continuum. So, if we put that aside as a gap that we would love to close, when you look into the near future or distant future, Dr. Bushnell, and what's the next big thing on the horizon? New interventions, new prevention tools, or something else entirely? What do you think?  Dr Bushnell: There are two things that I would mention. One is sort of the new category of anticoagulants, antithrombotics, the factor XIa inhibitors. We had an amazing presentation of the oceanic stroke trial at the International Stroke Conference, and this is probably going to be a game changer for the arsenal of antithrombotic therapies that we can offer to patients that do not have a reason for anticoagulation. So, they, they don't have atrial fibrillation, for example, or something else that requires anticoagulation. And so, the factor XI, asundexian, is the drug that they used in that trial. The safety profile is pretty amazing. There was very little bleeding complications and a great benefit in those patients with some degree of atherosclerosis, but, you know, of course, not enough to require carotid revascularization, but then also, um, small vessel disease and cryptogenic stroke. I think those are the three categories of patients, and that's a lot of the strokes that we see all benefited from this new drug. So, I think that's gonna be exciting. There, of course, it has to go through the FDA approval process, and so it might take a little bit of time before that's on the market, and we don't know how much it's gonna cost, but I think it is a, a major breakthrough. And of course, there are other similar medications in that category that are coming. And then I think the other thing is the emphasis on brain health and lifestyle factors and the things that we can do to prevent stroke and dementia because they are the same, essentially. Those are really important. And when we have someone in the hospital with a stroke or a TIA in particular, it's a great teaching opportunity for those patients to say, "Hey, here's what you can do to protect your brain." These are things that we always tell people to prevent a stroke, but just think about it as protecting your brain and keeping your brain as healthy as possible.  Dr Jones: That's a great message, and one that you get to share with patients directly. You're joining us today for this interview. You're on stroke service, so you're actively involved in caring for patients with stroke. What in your practice is the most rewarding aspect of caring for these patients? What is it that you find most rewarding?  Dr Bushnell: I've been involved in a clinical trial that has focused on managing blood pressure and also coaching and other aspects of stroke recovery. I think that has probably been the most rewarding aspect of my career. Until I was involved with this trial, I didn't necessarily do intensive blood pressure monitoring, but I'm seeing the benefits of having data from home, what those blood pressures are over a span of time. I see the immediate or intermediate effects of the blood pressure medication changes that I've made, and I see how the patients respond. So, I have to say that this is not part of usual practice, but I think it should be. And I think it's been incredible from the perspective of a neurologist who is really intensively trying to make the patients' lives better. And it's not just what I do, it's what the health coaches do as part of this intervention. And again, very similar to intensive medical management. So, I, I feel like I've been living it in a slightly different setting than in the CREST 2 trials. But there are other trials that have used the intensive medical management as approach as well. But I would say that's the most rewarding. I've seen people who've lost weight, who are physically fit, who are able to get off of blood pressure medications practically by the end of six months, and that's amazing. And then they continue doing it because they see the benefits.  Dr Jones: You've had a front row seat to a lot of that. That's really got to feel rewarding.  Dr Bushnell: It is, absolutely.  Dr Jones: You know, when you put it that way, it makes me want to go home and check my blood pressure, which I haven't done in a while. But I think that's a message to all of our listeners that we do have plenty of opportunity for risk factor optimization and following the evidence that has been generated and is being generated. Huge opportunity, not only at the population level, but I think the, um, individual patient level too. Okay, so now we're back to our Continuum Audio trivia question, and I'll repeat it for our listeners. How was warfarin discovered, and how did it get its name? Dr. Bushnell and I were talking about this earlier, so I'll just go ahead and share the answer. So, in the early 20th century in the U.S. Midwest, there were epidemics of a hemorrhagic disease in cattle, of all places, and this was eventually traced to moldy cattle feed that was made from sweet clover. And in 1940, researchers at the University of Wisconsin discovered that the anticoagulant in the sweet clover was a compound that was later synthesized for therapeutic use in 1954 as warfarin. And the name came from, uh, the support for the research. The research support came from the Wisconsin Alumni Research Foundation, or WARF, and the end of the word came from the underlying compound, which was coumarin. So that was a little bit of trivia that I had never heard. It's not in the issue, everyone, so you're getting something extra here on the podcast. But been using the drug forever. It still has its uses, even though it's become less advantageous than some of the newer agents. But-- And of course, Dr. Bushnell already knew that when I brought it up, but I just thought that was an interesting bit of history. Well, Dr. Bushnell, thank you for joining us. Thank you for such a great conversation about the latest in cerebrovascular disease. I learned a lot today. I learned a lot in reading these wonderful articles. I hope our listeners learned a lot today as well. I'm really grateful for your hard work on the issue, which I think will come in handy for junior readers and subscribers, as well as our more experienced neurologists as well. Sometimes it's hard to keep up with a rapidly changing subspecialty of our field. So, thank you for joining us today.  Dr Bushnell: Thank you for having me. It's been my pleasure.  Dr Jones: Again, today we've been speaking with Dr. Cheryl Bushnell, guest editor of Continuum's most recent issue on cerebrovascular disease. Please check it out, and thank you to our listeners for joining today.  Dr Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. Thank you for listening to Continuum Audio.

On this Make A Difference Minute, I have Steffenie Jenkins sharing the journey she and her family have faced as they searched for answers for their son, Jacob. Now 21 years old, Jacob is battling bronchiolitis obliterans, a rare and irreversible lung disease, and is receiving treatment through Mayo Clinic in Arizona. As Jacob's health declined, Steffenie found herself in a position many families know all too well. She could see something was wrong, yet finding answers proved difficult. Through countless appointments, tests, setbacks, and frustrations, she continued advocating for her son and pushing forward when it would have been easy to give up. Her message is one of perseverance, determination, and trusting your instincts when someone you love is suffering. Sometimes the path to answers is longer than it should be, but Steffenie's story is a reminder of the power of persistence and a mother's unwavering love for her child. If you would like to support the Jenkins family, visit GoFundMe and search “Jacob's Fight to Breathe: Help Us Continue His Care.” You can also email Steffenie at SteffenieJenkins@gmail.com for other ways to support. This MADM is brought to you by Bama Estate Planning by Attorney Harlan D. Mitchell, proudly supporting stories and the people who make our communities strong. Real stories. Real people. Real impact. News That Unites!™️

On tonight's show, I'm joined by Steffenie Jenkins as she shares the story of her 21-year-old son, Jacob, and the medical battle that has changed their family's life. After years of unanswered questions, Mayo Clinic diagnosed Jacob with Bronchiolitis Obliterans, a rare and irreversible lung disease. More recently, doctors determined the condition was likely caused by rheumatoid arthritis affecting his lungs, an extremely rare complication. Now, Jacob continues treatment while facing the possibility of a lung transplant in the future. This is a conversation about a mother's determination, a young man's courage, & a family's fight to hold onto hope through unimaginable challenges. Real stories. Real people. Real impact. News That Unites!™️

Host: Darryl S. Chutka, M.D.  Guest: Benjamin Lai, M.D.  Substance use disorders are chronic and often relapsing conditions associated with compulsive substance use. They result from a complex interaction of chemistry within the brain, often combined with genetic and environmental issues. Common substances involve alcohol, stimulants, sedatives and opioids; opioids commonly prescribed by health care clinicians. Early identification of patients and care coordinated with behavioral health specialists is the best approach to improved patient outcomes. The topic for this podcast is “Addiction Care and Empowering Non-Specialists”, and my guest is Dr. Benjamin Lai, A Family Medicine physician from the Department of Family Medicine at the Mayo Clinic.  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

Sig Muller is an author, motivational speaker, consultant, and founder. He was on the swimming team at Northwestern University in Illinois, where he earned his Bachelor's Degree in Industrial Engineering; following, he received his MBA from the Tuck School of Business at Darmouth in New Hampshire. His career includes leadership roles at Accenture, Ben & Jerry's, Mayo Clinic, UnitedHealth Group General Mills, and multiple startups. In 2024, he survived a sudden cardiac arrest that reshaped his mission, which led him to write and publish "Dying to Be the World's Best" in 2025. Sig makes his home in Minneapolis, Minnesota. 

Menopause Management In Women with Cardiovascular Disease   Guest: Chrisandra Shufelt, M.D. Host: Marysia Tweet, M.D., M.S.   Listeners of this episode of “Interviews with the Experts” will gain a practical, evidence-based framework for managing menopausal symptoms in women with cardiovascular disease or elevated CVD risk. Through discussion of patient selection, menopause-specific cardiovascular risk factors, and the evolving data on hormone therapy. Listeners will leave better equipped to individualize care and counsel patients with confidence.   Topics Discussed: Treatment for menopause symptoms in women with risk factors for CVD  Appropriate candidates for hormone therapy Which cardiovascular risk factors are attributable to ovarian aging (menopause) versus chronological aging? What does the current evidence show regarding claims that menopausal hormone therapy prevents cardiovascular disease? How might the FDA's removal of the black box warning from menopausal hormone therapy labeling affect clinician prescribing practices and patient decision-making?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode.   Podcast episode transcript found here.   Recorded on: 15-January-2026

"People want to work with the people they want to have a beer or a glass of wine with." Television monologue writer, author, and clean comedian Jan McInnis joins host Josh Seldin to prove that humor isn't just for the comedy club: it's a critical tool in the executive toolkit. Jan shares her front-line secrets from speaking to organizations like the Federal Reserve and the Mayo Clinic, showing leaders how to safely navigate the fine line of "too soon" comedy and leverage the humanizing power of self-deprecating wit. Josh and Jan dig into how leaders can command a room like a seasoned stand-up, manage corporate "hecklers" without losing power, and bypass standard corporate tunnel vision by intentionally scanning their environment for ironies. From coping with frozen salaries in Iowa to navigating truck drivers in a church basement, this episode is a masterclass in reading the room and breaking the ice when the pressure is on. Key Takeaways: ✅ The Energy Reset: How a single well-timed observation can instantly release the physiological tension of a room stuck in a low-energy or high-stress rut. ✅ The Anatomy of a Business Joke: Why leaders should avoid hot-button topics (politics, religion) and focus strictly on situational ironies and self-deprecating humor. ✅ Handling the Corporate Heckler: Learning from comedians how to diffuse disruptive, attention-seeking team members ("Bobs") without forfeiting your authority. ✅ Bypassing Corporate Blinders: How to trade presentation tunnel vision for sharp situational awareness by scanning agendas, environments, and team vibes. ✅ The Meme Advantage: Utilizing cartoons, idioms, altered acronyms, and visual memes to increase email open rates and reinforce dry corporate documentation. ✅ Starting Small: Embracing the "open mic" approach to management by testing out small, authentic expressions of humor before anchoring major company keynotes with it. Connect with Jan McInnis: Website: https://theworklady.com/ Substack: https://janmcinnis.sub... Instagram:  / jan.mcinnis Contact Josh: leadinquarters@gmail.com Follow Leadership in Quarters: @leadinquarters on Instagram, YouTube, and TikTok Artwork: Adam Powell Music by Bensound.com/free-music-for-videos License code: FK3H7T3WKW6EAGTE Artist: : Benjamin Tissot #LeadershipInQuarters #JanMcInnis #HumorInBusiness #ExecutivePresence #ApproachableLeadership #CorporateCulture #ReadTheRoom #JoshSeldin #YourGrowthAscent

It's Friday, May 29th, A.D. 2026. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Adam McManus and Jonathan Clark 180 Christian families denied communal water in India More than 180 Christian families in 32 villages across Chhattisgarh State in central India have reportedly been denied access to communal water sources and livelihood opportunities for the past three weeks as punishment for refusing to leave their Christian faith, reports International Christian Concern. Many Christian families in the Antagarh region of the district have been barred from using community rivers, ponds, taps, and hand pumps. At the same time, Christians have been denied work under a government employment scheme.  2 Timothy 3:12 says, "Indeed, all who desire to live a godly life in Christ Jesus will be persecuted." According to Open Doors, India is the 12th most oppressive country worldwide for Christians. Trump's accelerating squeeze on Cuba The Trump administration is bracing for the potential collapse of Cuba's totalitarian government as early as this summer, and has war-gamed new military response plans in case the island descends into chaos, reports Axios. President Trump will keep pushing economic sanctions to try to strangle the regime in Havana in a slow-motion constriction. This methodical squeezing of Cuba's communist regime is also designed to buy time for Trump — who's now engrossed in peace talks with Iran — to eventually focus on Cuba and decide how to bring about change there. The Cuba operation aims to eliminate Latin America's source of Marxist agitation and anti-U.S. activism ever since Fidel and Raul Castro led their successful revolution in 1959. To bring Cuba to its knees this year, the administration first focused on the island's lifeline: Venezuela, which is 1,200-miles south, and its socialist dictator, Nicolás Maduro. Venezuela kept Cuba afloat with shipments of oil that helped power the country and gave it a source of export revenue. Former Attorney General Pam Bondi has thyroid cancer Former U.S. Attorney General Pam Bondi was diagnosed with thyroid cancer shortly after her departure from office earlier this year and is now receiving treatment, reports USA Today. Bondi, age 60, was fired by President Donald Trump in April but is set to return to the Trump administration to serve on an advisory committee on artificial intelligence policy as she battles cancer. Thyroid cancer results from malignant cells growing in a person's thyroid gland, the butterfly-shaped gland at the base of your neck that makes hormones, according to the Cleveland Clinic and Mayo Clinic. These hormones regulate how your body uses energy, including metabolism, heart rate and blood pressure. Jill Biden wondered whether Joe had a stroke mid debate Remember this pivotal moment in the 2024 presidential debate between Joe Biden and Donald Trump? BIDEN: “Making sure that we continue to strengthen our health care system. Making sure that we're able to make every single solitary person eligible for what I've been able to do with the uh, with the COVID, excuse me, with, um, with dealing with everything we have to do with.  Look, if.  We finally beat Medicare!” As First Lady Jill Biden watched her husband stumble through the most cringeworthy portion of his disastrous June 2024 debate, she wondered if he had unknowingly ingested drugs or was having a medical episode on live television. In an upcoming CBS News Sunday Morning interview she said this. JILL BIDEN: “As I watched it, I thought, ‘He's having a stroke!' And it scared me to death.” However, at the time, right after the debate two years ago, Jill Biden said this. JILL BIDEN: “Joe, you did such a great job! You answered every question. You knew all the facts.” In her new biography entitled, View From the East Wing, she was far more candid. She wondered, “Is he short-circuiting? Is this a stroke? I felt like we were watching an AI hologram of the man we knew, and the hologram was glitching. Has he been drugged?” According to The Atlantic, which has seen a preview copy ahead of the June release, Jill Biden wondered, “Will people watching assume this is how he is all the time?” Bidens fighting to squelch embarrassing audio recordings Gary Bauer, founder of American Values and the co-host of Family Talk, wrote, “Right now, the Bidens are fighting to prevent closed-door audio recordings of interviews Joe Biden did from being released to the public. Why? Because in those interviews Biden couldn't remember basic events in his life. He couldn't remember when he was vice president. He couldn't remember when his son, Beau, died. He couldn't remember the advice his generals gave him.”   Bauer concluded, “And we all remember what Special Counsel Robert Hur said. Hur did not charge Biden for keeping classified documents because no jury would convict an ‘elderly man with a poor memory.' In other words, Joe was not mentally competent to stand trial.” Teenage worker bees drops to lowest level since 1948 The number of teenagers working jobs this summer is expected to fall to the lowest level since 1948. The consulting firm Challenger, Gray & Christmas predicts teens will gain 790,000 jobs in May, June, and July. That's down from 801,000 last summer. The firm noted, “Rising inflation, climbing oil prices, and a broadly cautious hiring environment are expected to keep the 2026 summer hiring total well below historical averages as employers and consumers rein in spending.” Welsh preacher John Penry pleaded for Welsh evangelism before execution And finally, on May 29,1593, 433 years ago today, Welsh Protestant preacher John Penry appealed for Christian pastors to proclaim the Gospel of Jesus Christ in Wales shortly before his execution under the reign of Queen Elizabeth I. John Penry wept for Wales. He noted that thousands of Welsh had never heard of Christ. He wrote, “O destitute and forlorn condition! Preaching itself in many parts is unknown. In some places, a sermon is read once in three months.” Penry proposed a system of lay pastors supported in part with voluntary gifts from the people. His attack on the neglectful behavior of the Church of England won Penry the undying hostility of John Whitgift, the Archbishop of Canterbury, reports the Christian History Institute. Having become a Puritan Separatist in his thinking, Penry could not accept a state-run system because, "The truth of Christ” could not be in bondage to an “anti-Christian power.” Because of such outspoken views, and his stern warnings to Queen Elizabeth I and her bishops, Penry had to flee. Because he dared to expose the Church of England for its neglect, John Penry was captured and treated to a travesty of justice. Some strong words of warning against the queen in his notebook were interpreted as treason. Archbishop Whitgift was the first to sign his death warrant. Penry was hauled off to be hanged on this day, May 29, 1593. A thin scattering of bystanders, none of them his friends, watched as the 34-year old departed this world at the end of a rope about four in the afternoon. He was not allowed to preach a final sermon. He had, however, written a lengthy letter to his four daughters named Deliverance, Comfort, Safety, and Sure Hope -- who ranged in age between 4 and four months. He implored them to follow the true faith. James 1:12 says, “Blessed is the one who perseveres under trial because, having stood the test, that person will receive the crown of life that the Lord has promised to those who love Him." Close And that's The Worldview on this Friday, May 29th, in the year of our Lord 2026. Subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com.  Plus, you can get the Generations app through Google Play or The App Store. I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

"There are a lot of specifics that nurses need to keep in mind as they are administering this herpes simplex modified virus to patients because accidental exposure is of concern both to the patient, to their family members, as well as to healthcare workers. I always recommend nurses wear personal protective equipment, such as a gown, safety glasses, gloves, and/or a face shield," Heidi Finnes, PharmD, RPh, BCOP, director of clinical ambulatory practice at Mayo Clinic and assistant professor of pharmacy at Mayo Clinic Alix School of Medicine in Rochester, MN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about oncolytic viral therapy.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 29, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge about the use of oncolytic viruses to treat cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs Episode 273: Updates in Chemotherapy and Immunotherapy ONS Voice articles: Cutaneous Malignancies Have High Response to Oncolytic Virus Plus Immunotherapy Oncolytic Virus Kills Tumor Cells While Supporting T Cells What Nurses Need to Know About Talimogene Laherparepvec for Advanced Melanoma Clinical Journal of Oncology Nursing articles: Intralesional Therapy: Consensus Statements for Best Practices in Administration From the Melanoma Nursing Initiative Safe and Effective Standards of Care: Supporting the Administration of T-VEC for Patients With Advanced Melanoma in the Outpatient Oncology Setting Oncology Nursing Forum article: Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma ONS book: Guide to Cancer Immunotherapy (second edition) ONS clinical practice resource: Safe Handling of Oncolytic Viruses ONS Huddle Card: Immunotherapy Association of Community Cancer Centers (ACCC) Drugs@FDA Hematology/Oncology Pharmacy Association (HOPA) Network for Collaborative Oncology Development and Advancement (NCODA) Patient Education Sheets To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "[Oncolytic viruses] can have direct lysis to the tumor cells themselves, or they can cause immunogenic activation. They release tumor-associated antigens and then proinflammatory signals, so think of T cells, natural killer cells, those sorts of things, that can convert to immunologically cold tumors. Those are tumors that are immune silenced into hot tumors which are now immune activated. By doing that, they recruit those T cells and other cells to the area to attack both the primary tumors. But that's also thought to be how they work on distant or noninjected sites as well. This immunomodulatory capacity has led to the reclassification of oncolytic viruses as a form of cancer immunotherapy. So, think of it kind of similarly to how we think of immune checkpoint inhibitors in recruiting immune cells and leaving our immune system in the on position. This is also kind of a form of immunotherapy." TS 4:35 "One of the toxicities I know that is of significant concern to patients, family members, and healthcare workers is the incidence of herpes infections. Systemic herpetic infections are extremely rare and usually more common in patients who may be immunocompromised. In patients who also have other immune-related diseases—such as vitiligo, vasculitis, pneumonitis, sometimes worsening psoriasis—because you're mounting an immune response with these types of things, sometimes you can see a worsening of those types of immune symptoms. But for the most part, these types of side effects are very well tolerated in most patients." TS 9:07 "Talimogene is generally transmitted via bodily fluids or touch. It's not airborne. Herpes simplex virus isn't an airborne type of virus. Another thing to consider is where are you going to inject this? Are you going to do this in your infusion therapy unit? Are you going to do it in a dedicated room? Who's going to escort the patient to the room? How is the virus going to arrive at the room? How will you clean the room and all of the laboratory equipment or any of the exam tables that may be in there? I think having all of that discussed and assigned mitigates the consternation that can sometimes occur—the fear that occurs with administering a virus that is thought to be fairly communicable." TS 15:44 "Helping patients understand how this works [is important] because hearing that you're receiving a virus, particularly a herpes simplex virus, can be scary to a patient. I think understanding that it's modified or essentially we're taking the parts out of it so that we can directly inject a portion that recruits immune cells to that area, because the goal is for the oncolytic virus to attack cancer cells and then destroy them by triggering an immune response in the body." TS 20:51 "Sometimes patients are very concerned about urine in the toilet, bodily fluids, kissing loved ones, holding hands, hugging, you know, am I going to infect my loved one because I'm getting this type of an oncolytic virus therapy? I like to reassure patients that they can continue to hold hands and hug their loved ones as normal. Viral DNA is usually only present on the injection site. And as I mentioned previously, we want to cover that injection site with an occlusive dressing, at least with talimogene, for up to seven days. And particularly, if those injection sites are at all oozing or weeping, active virus is usually only on that injection site itself." TS 24:14

Our great friend Bill Morice, the Mayo Clinic Big Knocker, was in town for a meeting so he stopped by the studio for over an hour of great discussion on a wide-range of health care topics. See omnystudio.com/listener for privacy information.

Our great friend Bill Morice, the Mayo Clinic Big Knocker, was in town for a meeting so he stopped by the studio for over an hour of great discussion on a wide-range of health care topics. See omnystudio.com/listener for privacy information.

Your skin has a biological age and for most people, it's not the same as their chronological one. Mayo Clinic published the SkinSpan framework this year specifically to quantify it, and the 12 Hallmarks of Aging now have a direct application to dermal tissue.This raises an uncomfortable question: if you're already optimizing everything below the neck with NAD IVs, peptides, and red light, why is the skincare on your face still operating on a paradigm from 1987?In this new episode of the Biohacking Beauty Podcast, we give you a preview of the keynote we're delivering at Dave Asprey's Beyond Conference and walk you through the 3-pillar framework that replaces traditional anti-aging skincare with longevity science in mind.Because the results you can feel today and results you can measure in ten years are not the same thing. And we think you deserve both.Let's dive in.What's Discussed:(2:29) The gap no one in longevity talks about.(3:06) Why your moisturizer is 38 years behind your supplements.(6:21) The 12 Hallmarks of Aging, decoded.(9:42) Pillar 1: The master pathway of skin aging.(12:18) Why NAD in a jar doesn't work (and what does).(14:22) The cellular housekeeping system that quietly shuts down with age.(15:17) The peptide that affects 32% of your skin's genome.(16:55) Pillar 2: The software updates your cells stop sending.(20:09) The PRP lineage that changed regenerative aesthetics.(22:54) Pillar 3: The pillar our community doesn't want to hear about.(29:09) The protocol, tiered by where you're starting.(37:55) How Young Goose fits into what you're already doing.(40:32) The two tests we're building to measure skin longevity.Find more from Young Goose:Use code PODCAST10 to get 10% off your first purchase, and if you're a returning customer use the code PODCAST5 to get 5% off at https://younggoose.comInstagram: @young_goose_skincareHead to younggoose.com/products/youth-body-cream for 20% off

Staci Miller, founder of Gen UX Consulting, shares her winding path from fashion design and psychology to human factors engineering in MedTech. Staci explains what human factors is—through stories from World War II aviation and modern healthcare—and why the FDA now mandates usability work to reduce catastrophic use errors. She breaks down formative versus summative/validation studies, the role of risk documentation (URRA/UFMEA), and why founders should think about usability as early as they think about risk. Staci also opens up about the challenge of starting a second business after losing her first in 2008, how she built Gen UX from $0, and the leadership lessons behind year-over-year growth.   Guest links: https://www.genuxconsulting.com/ | https://www.linkedin.com/company/gen-ux-consulting/  Charity supported: Feeding America Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 081 - Staci Miller [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and today I'm delighted to welcome as my guest, Staci Miller. Staci is the founder at Gen UX Consulting. Her expertise is in applying user-focused research to develop innovative solutions, and it's essential to the growth of any technology organization. As a detail-oriented and tenacious executive in human factors engineering and UX design, she has a proven record of elevating the end user experience and achieving targeted client outcomes. She has created innovative medtech and big tech solutions through a comprehensive user-centered development process, leveraging artificial intelligence and industry agnostic design tools to optimize products and services. In her current role with Gen UX, she's a key leader facilitating strategic company growth plans and service offerings while managing the capacity and workflow of the UX HF design team. Well, Staci, welcome to the show. I'm so excited to talk with you today. [00:01:49] Staci Miller: Me too. I've been looking forward to it all week, so I'm very excited to be here. And I don't know what the day has in store. I, I know that there was like a, a, a kit that you sent out and I didn't read it on purpose, so everything's gonna be organic. [00:02:03] Lindsey Dinneen: Perfect. Those are my favorite conversations anyway, so I'll take it and run. Some people I know really love to have the questions ahead of time, and others are just like, "Yeah, I don't want to know. I'm just gonna go off the cuff. Here we go." So, brilliant. All right, well, let's start, if you don't mind, by sharing a little bit about yourself, your background, and what led you to medtech. [00:02:24] Staci Miller: That is, those are my favorite questions. So, I have a background in fashion design, psychology. I spent most of my classes in cognitive psych, but it wasn't like a difference of degree, it was just psychology. And then I have a master's degree in human factors and ergonomics. So I went the psychology route and the design route. That's kind of my background. So when I graduated my master's degree, through my master's program, I was able to intern for both years and one was in tech, big tech. I interviewed and landed a, great one year long internship at Samsung, which was actually supposed to be just three months, and I stayed there for a full year. So they kept me through my whole, my whole semester, which is something they don't normally do, which was really fun. I mostly just said, "Hey, can I stay here for the year?" And they're like, "Great, no problem. Sure. We'll figure it out like that seems like a good option. We like you, you like us. Cool. We'll do that." And my second internship was in medical device at a company called Interface and Analysis. My, that was actually my internship. My second one was at Samsung, so I got to really look in like I, I guess you got the curtain. If you think about Wonderland and Oz and the curtain and being able to pull back the curtain between both industries, what did I like better? I ended up liking medical better, mostly because the research was more structured and not necessarily conversations about, "Yeah, so how do you feel about that? Did you like it?" Like to me, that's not really. What I would consider the best opportunity to gain data. Data to me, like there has to be like a clear objective as to what you're doing, the whys behind it, and what do you wanna learn. And I found that in, when I worked with engineers in medtech, they definitely had things that they wanted to learn, whereas in tech, they just had so much money. They were like, "Yeah, let's just see what people think about this." And I'm. Okay. And then when I would be really structured and I was working with people who didn't have backgrounds in research, had very strong, very good backgrounds in design, like legitimately awesome, they were leading the research and they were missing the boat. So the narratives started to be focused on the N of one. This one person said this really interesting thing, so let's base our whole design off of what they said. And I'm like, "Dude, wait a second. Wait a second. All of them said this thing about the design though, and like we have four or five data points about when you ask this question." They're like, "Yeah, but that's not interesting." And I was like, "Okay, keep my mouth shut. I got it. Move on." Like from that moment forward, I, it wasn't like "Staci, don't talk, it was more like this is how we design based on the narratives that we've learned how to, how to research on." And so it wasn't as I would say-- it wasn't considering the actual 360 view of the user. It was considering the really cool thing that happened this one time that was like totally an outlier. And it happened consistently when I was working in big tech. So I was like, uh, medtech, probably more my speed. And then my first job was at Abbott. [00:05:39] Lindsey Dinneen: Nice. [00:05:40] Staci Miller: And I ended up there. Yeah, [00:05:41] Lindsey Dinneen: Okay, great. Well. [00:05:42] Staci Miller: Cool. [00:05:43] Lindsey Dinneen: Lots of questions based on this incredible background. I want to go back a little bit. So fashion design, was this something that you grew up thinking, "Oh, this is what I wanna do and be okay?" Right. All right, so... [00:05:57] Staci Miller: it's all I ever wanted and I did that. So... [00:06:00] Lindsey Dinneen: Yeah. [00:06:02] Staci Miller: That's a, that's a great question. I think that my interest in fashion peaked around when I was 12 years old and during the time, Cindy Crawford and Naomi Campbell, and I was so fascinated by how beautiful these women were. And, and fashion was a thing in the nineties. There was like a lot of Dolce and Gabana around, and I loved it. And I couldn't wait to get my new print of Vogue every, every season. I loved Harper's Bizarre, and I would just pull pictures out of these models and what they were wearing. And then I would start you know, freehanding stuff and things like that. And I think a lot of people do that when they're really interested in clothing and things like that. And if you really think about it, fashion is art that people wear. So I was very attracted to that part of it. And it's all I wanted to do. So after high school, I went to FIDM and studied fashion design. And right outta FIDM, I started my first company in fashion design, and I was a clothing manufacturer, and we had 500 open doors in the United States and in Canada, and I was hoping to expand, but unfortunately 2008 hit and they hit it hard and fast and I lost most of my managing capital in the year that I think was my tipping point. So it was the, the year that I finally got a lot of traction and had a lot of repeat business and a lot of new business as well. And a lot of those new businesses just refused orders. Just from the east coast to the west, and it was just tons of money out that wasn't gonna come in. So there was really no way to, make that work after that, like I lost literally all the money I had in my business in like the span of, I would say three, four weeks. It was just mortifyingly scary. But I was young and people who are young are resilient and they move on and they find a new dream. And it took me a minute, like I didn't really know what the french toast I was gonna do. And I was like, well, I was still planning on staying in fashion and long, short, I was offered a job to do and run production for a one, a different company. So make sure that their goods were produced on time. Deal with the, the timing of all the orders, making sure the product line. So it was basically operations for manufacturing. And I was super excited about the job and I moved back to my parents' house at the time because things were just that tight financially for me. My parents were like, "Yeah, just, you know, come back, we'll figure it out." And I remember saying to my mom and dad, I'm like, "If this job falls through, do you mind if I just go back to school and stay here?" And they both started to laugh at me like, "Your job is fine, but if the sure why, why not?" And they, they thought it was crazy. And then I ended up back in school. So, they were like, "Whoa, that was really insane," 'cause that was in the end of 2008, starting 2009. And so the company rescinded their offer and they were really like, so sad about it, but they went to a market to sell their clothes and they got zero orders that year or something like close to that. So it was just, it was just a really intense time in the fashion industry and I was looking for jobs and I wasn't getting anywhere. So I only had an AA, and at the time that really didn't matter, but I went back to school and I'm like, "If I'm going back to school this late in age, I'm getting a master's degree." I had no idea what I was gonna get a master's degree in. I was like. I like clothes and design. We'll figure it out from there like that. And I was like, "Well, maybe I'll be..." this is crazy. But I was thinking about being a lawyer, like a property law lawyer. So, because when you are a designer in clothing, people can just knock you off. And you've seen that happen like pretty much everywhere. And people can just take advantage of your intellectual property and never pay you for it if they change enough of it. And so I was like, "You know, this would be something I'd probably be good at." So I went back to school thinking I was gonna go into that type of law. I took psychology courses and I took philosophy courses. And philosophy courses really do lean you, get you thinking very specifically about law. That's what philosophy was basically geared towards anyways. And you take these psychology courses and they're about people and how people process information, how people behave based on their behavior and things like that. So I thought the combination would be really good. Well, I ended up not liking, I did like philosophy, but philosophy's "let's think about thinking about it." And psychology is-- which is great. It's great, but psychology is like more applicable when you're interacting with others. And I found it super fascinating. And then I got really into like cognitive psychology and I'm like, "What the french toast am I gonna do with this? I can't do anything with cognitive psychology. Like I need to make money. I'm a grownup. This isn't ah, I'm gonna study underwater basket weaving and come out and go work in communications at Fox." Like I had to have an actual plan. So in my college at the time, there were these classes and they were like introductory to what you can do with your degrees. And that's literally where I found human factors. And there weren't very many schools that did it, but I was taking most of my classes at that point in cognitive psychology, which is how people process information, not their feeling based stuff. Like I didn't wanna have conversations with people about their feelings. Get that off of me. Like that's not, that's not my jam. I'm like, "Sorry, you're sad, but I'm not sad and I don't wanna be sad, so I'm gonna keep, keep going." And I'm like, "How am I gonna work this into my, you know, I love design, I wanna keep that in my background, and how am I gonna, what am I gonna do?" And so the study of human factors really is the intersection of design and research, and how people interact with said products based on the design. And you get to research that. And I'm like, "Sold. Good. I'm, I can do this. This is like this, I didn't even know this thing existed." This is crazy good. And I never looked back. [00:11:49] Lindsey Dinneen: Yeah. [00:11:50] Staci Miller: I got into a master's program the next year. I, and because I was in that specific program in San Jose State, that's why it was so easy for me to work for Samsung because it was in my backyard. And that's why it was easy for me to work for Interface Analysis because Tony was the owner of that company. Tony, he was my professor. So he just was like hiring people and I, I answered his response and I was like, "Hey, I, I'm looking for something." Do you like, he didn't say it was his company. He said, "I have a friend looking" and I'm, you know, like when I know I need to make some money, I'm gonna try to hustle up and make some money. So I'm like, "Hey, I'm open to that." He's like, "Why don't you come by my office and we'll talk?" And I was like, "That's weird." He said It was for some other, I'm like, "Sure, no problem." So I go to his office and he offered me an internship right then and there 'cause it was for me. "I just wanted to see who would respond," 'cause you are the only person that responded. I'm like, "Guess you're gonna hire me then." [00:12:37] Lindsey Dinneen: Amazing. All right. That's great. Thank you so much for that background. And it is so interesting how sometimes our paths are very, very windy to get to where we end up being and we Yeah, exactly. What, what ends up being a really good fit. But, so can you explain a little bit more about human factors, especially, maybe to help folks who have maybe some misconceptions or don't fully understand what it is just in general, but then also relate it specifically to medtech and why it's so important within the medtech industry? [00:13:11] Staci Miller: I can give you a story that probably would do both. So human factors was, was actually founded pretty recently in our timeline of psychology and understanding people. In World War II, there were a whole bunch of fighter pilots ejecting themselves from planes that caused, even in World War II, millions of dollars to produce and nobody could figure out what the problem was. They checked the planes. The planes were operating correctly. They did psychology, like psychological backgrounds on the people who are fighter pilots. I mean, they have to, to get into the military and to fly those planes, you have to be pretty good under pressure. They interviewed them, they were fine. They didn't have any breakdown of stress, and it wasn't happening on a small scale. This was happening on quite a large scale. So they, again, they went, they're like, "Okay, okay." Well, the military went back and " Well, it has to be the plane." So they looked through the plane, wasn't the plane, talk to the people, wasn't the people. So then the psychologist started to ask questions. They're like, "Well, if you're saying that it's not the person's emotional state and you're saying it's not the plane, well then what happened? Something had to happen. Something changed. What changed?" It turned out that the engineers had moved the throttle button with the ejection button in the planes. [00:14:31] Lindsey Dinneen: Oh. [00:14:31] Staci Miller: So the pilots were originally trained to hit the throttle button on the certain side that the throttle button was in the cockpit. So instead of hitting the throttle, because that was their original training, they hit the ejection button. So they ejected themselves out of the planes, which is why human factors was born. Those little changes that people don't understand about human beings. So when we learn something for the first time, because like even if you think about being a kid or being a baby, or learning a really tough lesson, right? You remember that lesson. And so what happens is that's your default setting. "This is the lesson I've learned. This is how I react." Now for that lesson, it doesn't matter if it's like an emotional exchange or if it's a physical one. So because they were taught where the, the pilots were taught specifically where the throttle was in the first place when they were under attack and they were in a high cognitive loaded space, they went back to their original training. [00:15:30] Lindsey Dinneen: Mm-hmm. [00:15:32] Staci Miller: And then the engineers were like, "Well, we told them. We told them." So, so, because they didn't wanna take the blame, right? Nobody wanted to take the blame ruining millions of dollars of planes. So this same type of thing happens in the medical industry. I mean, you can see it pretty easily, right? So you're trained on System X. There's an update, a 510K release to it. The system works differently. Errors are made, people are hurt. [00:15:57] Lindsey Dinneen: Mm-hmm. [00:15:58] Staci Miller: That's how it translates to medical. So aviation was a really big part of human factors and it still is to this day. Like NASA used to hire quite a few of my classmates. And I know that Boeing and a lot of those other, even BMW hire people that do what I do for a living and test the responses during drive time. And if you think about it, if you look at a Tesla versus a BMW, those are very different driving experiences. Like I had to relearn how to drive a Tesla, right? And like it has a one pedal situation. So now when I get into regular cars, I'm like, "Wait, what? What am I doing? What? What kind of car is this? Like how do I drive this thing again?" I know that sounds silly, but it, it's true 'cause you kind of just get used to the thing that you have. And that's exactly why human factors is prevalent in medical device or in aviation or in, you know, like any kind of like navigation systems. The reason the FDA mandated it is because a lot of products were coming to market and there was a very large influx of critical catastrophic errors in hospitals. People were suffering consequences of bad interfaces or lack of instructions on products. I know that there were a lot of intravenous medications given that weren't supposed to be IV medications in like in certain-- yes, you're supposed to inject it, but not. Intravenously and those charged caused people to perish. So that's when the FDA stepped in and said, "Okay, we were asking you as a favor to do these usability studies, but now officially they're part of your risk requirements and they're part of your requirements to get to market." And I think that happened about the time I graduated grad school, around that time. So about 15, 16 years ago. [00:17:50] Lindsey Dinneen: Okay. Yeah. Well that's a fascinating story, and I'm sorry that that is the impetus for the results that we have today, but also how incredible that that is something that's being prioritized and mandated now. And I'm wondering too, when a startup company is developing their technology, how soon should they be thinking about human factors, usability, UX/UI. [00:18:17] Staci Miller: As fast as they're thinking about risk. if you're already thinking about risk at phase zero, that's when you should be thinking about usability and UI and interactions based on user processes, because that's when this kind of conversation really needs to start with regulatory, with your team, with the engineers. So even if you don't have a human factors engineer on staff, like you can find a company that can give you like some fractional support, just, you know, to talk to and to understand what their, what, what their responsibilities are, and what their requirements are to get to market. I have found that a lot of founders don't think that it's a requirement. And I, and I'm really not sure why, but that's been happening a lot lately. [00:18:59] Lindsey Dinneen: Yeah. So because it's a requirement, because you should be thinking about it from the get go, what are some things that you've seen work really well in terms of, putting together this kind of this testing and whatnot versus things that might seem like they could work. Like perhaps somebody feels that they could maybe do some of this testing themselves. You know, just, just things that maybe people who aren't really familiar with all the regulations would perhaps do, and that could cause problems down the road. [00:19:32] Staci Miller: So there's a, these are all really great questions and let's, let's unpack the idea of research, right? So some people think that research is finding out if somebody is happy about a product and would use it, like product market fit, right? Some people do marketing for that, and I can, that's the type of research that is not technically human factors, but it is something that Gen UX can do, right? So it's just research. I, I call it like insert white meat or insert protein. We can do the research, right? So when it comes down to it, there's, I would say that research is split into two buckets, which is UX/UI, which is very popular and people understand that, which is a formative in the FDA guidance and then validation slash summative. So the validation studies are very clean cut. So I'll explain those first. And they are to validate that the user can use the system in its environments safely. So the alpha for that is the user is successful at using this product and the uses, uses and use environments correctly and safely. And this is all based on your risk documentation from your URRA or your UFMEA. Some people use ADFMEA, which is based on design, and I suggest that they don't use that because that focuses more on the system than it does on the user. And the FDA has really cracked down on that. So if you are a founder and you think you can get just one system, ADFMEA, you are probably already starting off on the wrong foot. Make sure you have your own usability. Because human factors work really focuses on two things in the medical industry. One, it focuses on helping develop the device while breaking down risks. So if you have mitigations and your system's designed a certain way to avoid a risk, that's very important, and that's really also usability testing. And I can explain this in two ways. I've worked at Meta, I've worked at Samsung, I've worked at a lot of different big tech companies, and I've worked at a lot of medtech companies. So I think that people think that human factors is different than user research, and they're right. Human factors is much harder than user research. And you really actually need a background in research methods and an understanding of how the application of research works. Formatives can be used for two reasons. One, to support the need of the product in use and to check how people are actually using the system in real life. So sometimes people are really good at thinking-- so engineers are amazing at building systems, right? I can't do what they can do. I'm not gonna pretend like I can. What I can do is help them build it for their end user, because a lot of the times engineers think very differently than the average human being. They're much more educated. Schooling for engineering is extremely difficult. A lot of it's mathematical computations, understanding actual physical properties of things in their environments and how that they work, right? So those are the things that engineers think about all day long. That's fine. I think about the user all day long. So you can create a system that an engineer thinks that is fine, but then the user is " I don't really know how to use this. What are you talking about?" Right? And so that's what user research informatives avoid. They avoid, they break down risk and they are able to help form the product. So those, those user research studies, like before, let's say phase zero to phase four in a market cycle, if phase five is market release, are for those things. And then as you get later in the cycle, you wanna do more rigid research, that's really breaking down the risk and really focusing on the user interactions within the system and med device. And making sure that they're assessing the risk based on your user, but they're very specific to the user interactions that are critical tasks and higher. Or things that lead up to the critical test and come away. So like you have to be able to do the steps before, do the thing that's really hard to do, that could hurt somebody and then make sure coming away from them you don't cause any harm either. That's the best way to look at these types of tests. And we do the exact same thing in validation for systems. So, in software you test to see if the software can do the thing that it's supposed to do. When you check that box, the software does the thing and it did it, and we're good to go. You do the same thing with mechanical engineering. The system has this, this range of motion here and this range of motion here, and it doesn't deviate from plus X to plus Y and therefore the system does what it's supposed to say. So you're verifying and validating that the system does what the system is planned to do. It's really no different in users, it's just that you're dealing with human beings and it's not, it doesn't work the same way, right? Because like people are variables no matter what. And that was really long worded. So there's like tons of different research to do, but if you don't do your summative and you don't do your risk documentation, you're not getting to, you're not gonna get to market approval. Just, there's no way. [00:24:34] Lindsey Dinneen: Yeah. Thank you. Yeah, that is incredibly helpful insight. And you know, so I wanna go back to, you had this company before, right? So you had already built a business and it was thriving, and then unfortunately life intervened a little bit. When you went to start Gen UX, did you have moments... [00:24:57] Staci Miller: Of PTSD? [00:24:58] Lindsey Dinneen: Of, yeah. [00:25:01] Staci Miller: Yes. [00:25:01] Lindsey Dinneen: Yeah. [00:25:02] Staci Miller: Yeah. I had major PTSD. Like I, so the concept of Gen UX was a play on words like, so I'm a Gen Xer, no biggie, but like I think that every Gen Xers, millennials, I feel like both of our generations very much identify with our generation. And I thought it would be kind of a fun play on words to identify to people that are also Gen Xers that, yeah, we do UX work and we're Gen UX, as a Generation X, like it was very important, right? So I kind of came up with that idea, thought it was cute. But at the time I was working for Meta, and Meta had been doing quite a bit of layoffs at the time. Nothing wrong with that, that happens with every company. But I have survived in Medtronic and Abbott and all these other companies. I had survived so many rounds of layoffs. I'm like, "One day my number is gonna be, it's just, it's just gonna happen." So, we started at Meta internally, really like they, they were very open and honest with people. They're like, "This is when this is gonna happen. We are gonna lay off more people. This is when this round is gonna happen. We're gonna lay off more people, and then this is the final round and this is when we're gonna lay off these people." So each of our groups of things like, so it was like engineers, lawyers, researchers. Like we, we had timelines that we knew if, if it was gonna happen, this is when it was gonna happen, this would be the day. [00:26:17] Lindsey Dinneen: Yeah. [00:26:17] Staci Miller: So I started to really think about what that meant, and I'm like, "Okay, well I'm not gonna start looking for jobs right away because I want my severance package." I definitely wanted that 'cause I, and then I wanted a break if I could have it. So I was like, okay. I, in between working at I was working at EDA as a contractor and that was super fun. Like I had my own time kind of, and I enjoyed the work and I got put on other projects whenever they needed me. And it was like, but I was constantly on a project, so I'm like, "I, maybe I'll go into doing IC work by myself" and I'm like, "No, I can't make enough. If I'm gonna do this, I'm gonna build something." And then I'm like, well, I started to talk to my friends every single one of my friends, including Interface Analysis' owner, Tony Andre was like, "Start your own business, Staci. Start your own consulting firm, just do it. Don't even look back. Just do it. People will end up coming to you because you know how to do this." He's like, he's it's, "You know, the first years they are what they are and everybody knows what that looks like. It's, it's rough. You have, it's like a mental game. You're like, I am gonna do this. And you just have to be consistent and can continue down your path. And more and more people will show up." And that's been true every year. But that's how GenX was started. And yes, there was this whole trepidation about, "Am I gonna make it? Am I gonna make it through this?" And I was like, "You know what, Stac, you're starting in a recession in your, in your industry. If you can get it done, if you can get two years in and be successful, you're fine." I'm in year three. [00:27:50] Lindsey Dinneen: Yeah! [00:27:51] Staci Miller: Yeah, I mean, year three, woohoo. And we're increasing 50% year over year in year three, and I started it with $0. So, and I'm not, I'm not saying like a hundred to 50, like $50 to a hundred, we're, we're talking a couple hundred thousand dollars here, a couple hundred thousand there. But it's modest and I do expect that growth, and I do expect that to continue. And the other thing I think about is becoming very malleable in, in your spaces, like what's working for you and what doesn't work for you. But I feel like that's kind of off topic from what you asked. But yeah, I had PTSD gave myself at least two years and I'm like, "I can do anything for two years. If it doesn't work out, you know, like I have everything that I have and I can go back into corporate if I need to." And I really, I really was tripping, like just to be nineties about it, I was tripping. Like I was really like, "You know, I don't know." And my husband was like. He was my biggest cheerleader. He was like, "You've gotta do this. He's you're gonna, you're gonna be able to do this. You have something that I don't have. You're really great at networking people like you." I'm like, "Do they really like what?" And he's, " No, people like being around you. You make friends easy and people really do enjoy being around you and they like know that you're smart and you're gonna be able to do this." So, that's how this all started. And yes, I was really freaked out when I first started, but every day when I had bad days, I'm like, "Everything always works itself out." [00:29:14] Lindsey Dinneen: Yeah. [00:29:14] Staci Miller: "Have you ever not been in a situation where everything works itself out?" "No. No." So I'm like, "Well, if I, if it doesn't, I'll get a new dream, but I don't-- once you hit this, this year, like year three and you know you're still growing, you don't have to get a new dream, you just keep going and you're like, this dream is happening. I'm gonna keep it going." [00:29:34] Lindsey Dinneen: Yeah. What was it like building a team? Did you start off as a one-woman show, or did you have support at the beginning? How did that work? [00:29:43] Staci Miller: So at first, actually my designer's father was working with me and he called me out of the blue and he's " Hey. I have this client, she doesn't have any human factors person working with her, but I know that she needs it and do you wanna talk to her? I know you're not working at Meta," because I put on my, oh. LinkedIn profile Open to Work. So he called me like within two days, like seriously, like people started to call me and that was when I was already like, "I'm gonna do my own thing. I'm just gonna do my own thing." So the universe just brought me a gift, right? And I met this first client and I started to work with her, and at first everything was super cool. The first year it was great, and I really liked working with her, but she also needed a couple of other things. She needed an IFU and she needed design quality assurance. I'm like, "Check, check. I can get both those things done." So I called my friend Maria, "Hey, do you wanna work with me? She's " Hey. Yeah, totally." Because we had already worked together and we knew each other pretty well. So it wasn't like it was difficult to make that connection. And, and she knows my personality. I know her personality, and I know we both work extremely hard and we have that in common. So I wasn't, never, would I be worried about Maria. And then I found I wasn't, I didn't even have a designer yet on staff. And I found someone who used to do instructions for use for a different company I worked for. I called him like, "Hey, can you do this?" He's " Yeah, yeah." So I got all that done for this other client. I'm like, "I can do this. I can do this. I can, I can find people." I know so many intelligent people who love what they do and have a fire for it every day. And then the evolution started to happen. And then I asked someone to work with me to do sales, and then they said, "Yes." And then we started to pitch people that I was friends with and knew, and sometimes they said yes, and sometimes they said no. I think the first year, I think I pitched over like $4 million in business and I got 20,000. No, I got, I got 80,000, something like that. Something, something small and I'm like, "Why am I pitching so much? This is like taking so much time outta my day," that I found someone to work with me. His name was Adam and I still actually work with Adam and he, but he's a big picture guy and he started to work with me a little bit and help me like navigate through some things. Even to this day, we talk and he's not fully, fully, fully on onboarded, but if, if some. Of the clients that he lands do come on board, he will be back on board and he will be working with me again. And then I had a salesperson this last year and I realized just I needed more of a hunter-gatherer. So like we're just going in a different direction, right? So I had that, and then last year my goal was to bring my designer Maddie on full-time. And I was able to do that too. So everything that I've kind of just said, "I'm gonna do this this year, I've been able to do this year." And I'm not taking this lightly. Like I have a board of directors, which are people who are, have different perspectives on finance because that's my weakest link, I would say. A professor at UCLA, his name's Sean Pat, also a good friend of mine. He's on my board. And my brother-in-law and my nephew, who is new in his life and on his journey, is on my board as well, and I kind of wanted him on my board so he can see what it looks like to be an entrepreneur and see what growth looks like year over year because he is already working for companies. He's, he's like 25, I think, and he's already being groomed to be in upper management. He's got upper management written all over him as like the, as like people would say in like cute little circles. And then my my brother-in-law, he is one of the CFOs at Mayo Clinic, so these are people who have some in medical, some in finance, some in finance, in medical, just helping me like grow. I throw things past them and they help, you know, make decisions for the year. And they tell me like, they give me feedback and, and work through things that I'm doing and what they think is right, what they don't think is right. And sometimes I listen, sometimes I don't. You know, like... [00:33:28] Lindsey Dinneen: Well, yeah. [00:33:29] Staci Miller: Just really depends like where I'm at and what I wanna do and where we wanna grow. [00:33:34] Lindsey Dinneen: Yeah. Excellent. Okay. So I'm curious, especially within medtech specifically, are there moments that really stand out to you as just affirming, "Oh my goodness, I am in the right place at the right time." [00:33:49] Staci Miller: Things keep happening, so, every time I speak, like I, I spoke at Project Medtech, people bombarded me. They're like, "We wanna work with you. We wanna work with you. We should talk, we should talk." Anytime I go to a symposium I walk away with two or three leads. People coming up to me, "Oh, do you do this thing? We should really talk. We should really talk." So, just being in the situation like that kind of tells me that I'm in the right direction. And the other thing is we're growing year over year. If you take a 10,000 foot view of where I was year one versus year three now, very, very different. Extremely different. And like I said, I do have, I do have other consultants that work with me. I don't want you to think it's just like a two person shop. It's not, there's other consultants that work with me but they're as needed. They're not full employees, which I think is really helpful in a situation like this. If you're a founder starting up from scratch and you're not, you don't have, I'm not trying to get angel investors. I'm not trying to get people to push money into my company. I am building it literally from zero to whatever it is that I make. And so that, that's a, what I would call like a slow burn of, you have to build your foundation, you have to manage to the capital that you do have, and then you, then you go to the next level and you do the same thing and then you do the same thing. And there's a lot of consistency with the business now, and I see a lot of people targeting me for that consistency. And as, as we are growing, like people are engaging with us on a different level, which is exciting to see. That's always exciting. [00:35:20] Lindsey Dinneen: Yes. [00:35:20] Staci Miller: That's kind of how I know. Yeah. [00:35:23] Lindsey Dinneen: I love that. Awesome. Okay, so pivoting the conversation a little bit just for fun. [00:35:28] Staci Miller: Cool. [00:35:30] Lindsey Dinneen: Imagine that you were to be offered a million dollars to teach a masterclass on anything you want. Could be within your industry, but it doesn't have to be. What would you choose to teach? [00:35:40] Staci Miller: That's a great question. I love, I think it's very important when you do what you do for a living to have something that isn't that for yourself. So I, there's very specific ways as to how I unwind at the end of the day. One of those things is cooking. I would totally do a masterclass in being a home chef. Like I'm, I'm not even a chef like that. I've never gone to culinary school, but I absolutely, I make my own breads. I make chutney sometimes when, when I want some. I would do a masterclass on-- I'm not Gordon Ramsey. I'm not Thomas Keller. Here's what it looks like to be a home cook. And here's the, the five things that you actually need. And this is what you should learn how to make first. Like I remember the first time I was trying to make pasta or something, I boiled the water to death. There was no water left in the pond. Like I didn't even know what I was doing. I, maybe I walked away from it, I don't know, but I destroyed the pot. My mom's " What were you doing?" I was like, "Making pasta." And she's " What, what, what happened? You ruined the pot." I'm like, "I'm not, I just did it wrong." So I would probably do a masterclass in how to just take that first step learning how to make your own food, right? And talk about food 'cause I like food. There you go. That's what I would do. [00:36:52] Lindsey Dinneen: Love it. I love food and I love talking about it. So, that sounds like a great class. [00:36:58] Staci Miller: I would do, I would totally do it. [00:36:59] Lindsey Dinneen: Okay, and then how do you wish to be remembered after you leave this world? [00:37:07] Staci Miller: This might be dating me, but Roy Orbison who wrote the song, "Pretty Woman" that was also in the movie, "Pretty Woman" wrote that he "just wanted to be remembered." And I thought that was really interesting. And I think that everybody knows that song knows that it's the guy like, I don't know if you know like the artist, but I think even to this day, that song, generationally, people know that song. I don't know how I wanna be remembered, but this is how I wanna impact the world. So it's kind of like that, but kind of not. I believe that knowledge transfer is the most powerful thing that we have amongst generations. And I want the next generation to be better than me, which is probably, in my opinion, I'm kind of kind of strict about this, probably a tall order, 'cause I'm like very picky. But, I have mentored and, and taught people my craft, and I want them to be better than me so they can mentor people and be better at this craft. So if I leave one mark on this world, it's that I have taught somebody what I know how to do and I expect them to do it better than me. And I don't mentor just anybody. So if I'm mentoring you is, and I'm putting all this energy into you, you better, you better bring it. And the people that I have worked with and have mentored are doing extremely well in their careers, and that's, that's kind of a thing that I like about, like what we do and how I do it. So I don't know if I would be specifically remembered for that, but I do know that it would move our industry forward and that makes me happy. [00:38:39] Lindsey Dinneen: I love that. That's a beautiful legacy. All right, and then final question. What is one I know, what is one thing that makes you smile every time you see or think about it? [00:38:52] Staci Miller: When I see what I'm building or, or how I'm building it in the future and I really go deep within my, my consciousness about this is what I'm gonna do next. This is how I'm gonna do it. This is what makes me feel really alive. I get so excited. I get like goosebumps. I start smiling. I, I'm a big-- I don't know if you do this, Lindsey, but I do this-- I kind of dance around a little bit. Like I dance when I'm making food, I dance and most people dunno that about me. But I, but my closest friends I remember I was working with this one guy and he looks at me, he's " Do you ever stop dancing?" I'm like, "Nope. Nope, Nope. Gotta dance." So all that stuff like starts to happen. And I just get really excited about the things that I'm trying to build, what I'm trying to master in my own world, what I'm trying to create. And that's what gives me like so much excitement. And then a number two would be my cats, because they're ridiculous and I love them and they give me so much love and they make me smile all the time too. [00:39:52] Lindsey Dinneen: Oh yes, those are great answers. I love that so much. It is exciting to see. Dreams come true. I can totally understand that answer of getting the, the excitement, the tingles, and then yeah, I, yeah, I, I obviously relate to dancing around all the time, and especially like celebratory dances. They're, my celebratory dances are the goofiest, most ridiculous things you've ever seen, but I'm happy! So. [00:40:20] Staci Miller: As long as you're happy, that's all that really matters, right? Like that vibe that you're putting out there and the happiness and the giddiness, like the things that I'm building in my mind, like they haven't happened yet, but I'm dancing like they have, you know, because I hope that they do. Like there you go. And I think that's important. I love it. [00:40:35] Lindsey Dinneen: True embodiment of the vision. I love it. Well, well, Staci, this has been a great conversation. Thank you so much for your insights and your stories, and we are so honored to be making a donation on your behalf today to Feeding America, which works to end hunger in the United States by partnering with food banks, food pantries, and local food programs to bring food to people facing hunger, and also they advocate for policies that create long term solutions to hunger. So thank you so much for choosing that charity to support. And gosh, I just wish you the most continued success as you work to change lives for a better world. [00:41:15] Staci Miller: Thank you, thank you. It was so much fun being with you today. I appreciate this and it was so much fun to talk about. And yeah, I can't wait to see you in the next couple weeks too. So we'll see each other soon. [00:41:26] Lindsey Dinneen: Yay! Sounds good. Well, thanks again and have the best rest of your day. [00:41:32] Dan Purvis: The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world.

Photo courtesy Great Lakes Indian Fish and Wildlife Commission / Facebook All eleven federally recognized tribes in Wisconsin have seats on a new committee aimed at protecting wild rice. Chuck Quirmbach reports. Gov. Tony Evers (D-WI) has announced his 24 appointees to the Wild Rice Stewardship Council. One member, Gloria Waabigwan Wiggins (Bad River Band of Lake Superior Chippewa), works for the group Wisconsin Native Vote. Wiggins also keeps up a tribal tradition, protected by a 1983 federal court ruling, of gathering wild rice in the ceded territory of Northern Wisconsin. “I’ve been harvesting wild rice, manoomin, with my husband for say, the last 9-10 years. Our powwow, our celebration of manoomin, is in August. So that’s a very important event for our community.” Wiggins says wild rice is also part of a sacred migration story for the Anishinabe, Indigenous people of the Great Lakes region. But tribal and state officials report low production of wild rice in recent years, due to factors like windstorms and very heavy rainfall, and long-standing threats like water pollution and excessive waves from boats. Another member of the new Stewardship Council, Eric McLester, helps direct environmental policy for the Oneida Nation. He says the big picture concern is climate change. “The amount of rain, water levels. It’s important to not have huge increases or decreases in water levels. Drought certainly impacts the wild rice beds.” McLester says the Oneida have restored about 35 acres of wetlands for wild rice production in recent years. He hopes the tribal members on the wild rice council can share best practices for the resource. It’s also possible the committee will propose new regulations to protect wild rice. A First Nations family in Canada is demanding answers after 24-year-old Jaali Sutherland-Weenie died during childbirth after reportedly being diagnosed with pre-eclampsia while 36 weeks pregnant. Family members say Sutherland-Weenie, from Beardy's and Okemasis’ Cree Nation in Saskatchewan, sought medical care in the days leading up to her death and raised concerns about symptoms linked to the dangerous pregnancy complication. According to the Mayo Clinic, pre-eclampsia causes high blood pressure during pregnancy and can quickly become life-threatening for both mother and baby if not closely monitored and treated. According to relatives, Sutherland-Weenie first went to a hospital in Rosthern before being transferred to Jim Pattison Children's Hospital and later to the labor and delivery unit at Royal University Hospital in Saskatoon, where she died on April 26 after giving birth to her daughter. Her death is now drawing attention from Indigenous advocates and community members who say Indigenous women continue to face inequities in maternal health care and are too often dismissed when reporting pain or complications. Loved ones are calling for accountability and a full review into what happened. Community members have also taken to social media to share condolences and call for better protections for Indigenous mothers navigating the health care system. The Saskatchewan Health Authority says a review is underway. Blayne Morin, Sutherland-Weenie's partner, said during a news conference held at Wanuskewin Heritage Park in Saskatoon, Saskatchewan earlier this week, he plans to attend her graduation ceremony next month to accept her degree on her behalf. Morin says the couple wanted to build a better life for their daughter than the ones they experienced growing up. “The family and I will be attending her congregation next month, taking her degree, and we planned so much for our baby before she made her appearance here. We didn't want her to grow up like how we did, breaking the intergenerational trauma.” Sutherland-Weenie leaves behind a newborn daughter and a grieving family now hoping her story raises awareness about the warning signs of pre-eclampsia and the importance of timely medical care. Get National Native News delivered to your inbox daily. Sign up for our daily newsletter today. Download our NV1 Android or iOs App for breaking news alerts. Check out today’s Native America Calling episode Thursday, May 28, 2026 — Exploring home, culture, and personal resolve with writers Joan Kane and Sherman Funmaker

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, speaks with William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, about Ebola, hantavirus and takeaways from a recent healthcare conference. Later, she welcomes Elli Theel, Ph.D., a microbiologist in Mayo Clinic's Department of Laboratory Medicine and Pathology, to explore vector-borne diseases.Top industry topics (00:04): Dr. Morice highlights key topics from a recent major healthcare conference, including AI and payment reform.Infectious diseases in the news (04:04): Overview of hantavirus, Ebola, and why laboratory medicine is important during outbreaks. Growing prevalence of vector-borne diseases (06:48): Insights on the growing prevalence of vector-borne diseases.Testing options (09:45): Understand the different types of testing available for pathogens and when it is best to use each one. Innovation and discovery (17:05): Discover emerging pathogens and advances in detection.Protect yourself (19:41): Learn easy ways to protect yourself and your family from vector-borne diseases. Note: Information in this post was accurate at the time of its posting.ResourcesForbes: Is hantavirus an emerging threat? What you need to knowVector-borne diseases by geographic regionVector-borne diseases: The right tests for detection and diagnosisLearn the ABCs of ticks

Brain donation is helping researchers better understand why Alzheimer's disease and related neurodegenerative disorders develop, progress, and affect people differently.Dr. Melissa Murray is a professor of neuroscience at Mayo Clinic in Jacksonville, Florida, where her research focuses on the biological changes, including tauopathies, that drive Alzheimer's and related neurodegenerative disorders.. At Mayo Clinic Florida she helps direct one of the world's largest brain banks focused on these diseases, giving scientists access to donated brain tissue that can reveal details about diagnosis, disease progression, genetics, resilience and risk that cannot always be seen during life.In this conversation with Being Patient's Mark Niu, Murray explains what tauopathies are, how tau and amyloid contribute to Alzheimer's disease, and why brain banks are essential to understanding the many ways dementia can appear. She also discusses how brain donation can support biomarker development, genetic discoveries, and more specific diagnoses. She emphasizes that brain donation also offers families answers and helps researchers work toward better ways to detect, treat, and ultimately prevent neurodegenerative disease.----If you loved listening to this Live Talk, visit our website to find more of our Alzheimer's coverage and subscribe to our newsletter: https://www.beingpatient.com/Follow Being Patient: Twitter:   / being_patient_  Instagram:   / beingpatientvoices  Facebook:   / beingpatientalzheimers  LinkedIn:   / being-patient  Being Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia. Check out our latest Live Talks: https://beingpatient.com/live-talks/

Welcome to Episode 091 of the Beyond the Diagnosis Podcast. In this episode of Beyond the Diagnosis, Kathy sits down with hematologist Dr. Richard Godby from Mayo Clinic to explore the rapidly evolving role of artificial intelligence in rare disease and healthcare. Together, they unpack how AI is already helping patients and physicians navigate complex medical information, shorten diagnostic journeys, improve advocacy, and potentially accelerate research and treatment development. Dr. Godby also shares practical guidance on how patients and caregivers can begin using AI thoughtfully and responsibly while understanding its limitations, risks, and ethical considerations. Whether you're curious, skeptical, or already experimenting with AI yourself, this conversation offers a fascinating and hopeful look at how technology may reshape the future of rare disease care. Let us know what you think! Leave us a review, drop us a comment or share an idea for a future podcast with us at podcast@histio.org.   Take a screenshot and tag us @histiocytosis_association on Instagram. We'd love to hear your feedback!  Be sure to subscribe so you can be notified the moment a new episode of Beyond the Diagnosis is released.   Resources mentioned in the podcast: Watch Dr. Godby's presentation on AI for wAIHA Warriors hereFollow the Histiocytosis Association on social media: Facebook: https://www.facebook.com/histio Twitter: @histiocytosis Instagram: histiocytosis_association YouTube: https://www.youtube.com/@Histiocytosis  Music: “Heroes” by Noah Smith  

Host: Darryl S. Chutka, M.D.  Guest: Michael Mueller, M.D.  Fibromyalgia is a chronic health problem commonly seen in a primary care setting. It can be challenging to diagnose and even more so to manage. It can have a devastating effect on a patient's lifestyle, and patients will commonly go from provider to provider seeking relief for their chronic symptoms. We now have a better understanding of the pathophysiology of fibromyalgia; unfortunately, the treatment remains less than optimal. What do we know regarding the cause of the symptoms in fibromyalgia? How can we efficiently establish a diagnosis in patients with the condition without excessive testing? How do we explain the disorder to patients and what's the long-term outlook for patients? These are some of the questions I'll be asking my guest, Dr. Michael Mueller, an internist in the Division of General Internal Medicine at the Mayo Clinic as we discuss “Fibromyalgia”.  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

Long COVID isn't just lingering fatigue. It's a complex, often life-altering condition that can follow even mild or unnoticed infections. Listen in as Mayo Clinic's Dr. Stephanie Grach breaks down what we really know about Long COVID, who's at risk, and why believing and individualizing care for patients is absolutely critical.   In this episode, Therese Markow and Dr. Stephanie Grach discuss the emergence and impact of Long COVID. Dr. Grach explains that Long COVID affects an estimated 18 million Americans with a wide variety of symptoms that can manifest differently from patient to patient, influenced by a variety of factors, such as viral variant, genetics, and immune responses. Dr. Grach emphasizes the importance of individualized treatment and highlights ongoing research and the need for better understanding and management of this complex chronic condition.     Key Takeaways: Long COVID can look very different from person to person, with over 200 symptoms. However, common symptoms can include fatigue, brain fog, shortness of breath, changes in smell, and more, affecting nearly every organ system.  The larger proportion of people with Long COVID had multiple COVID infections, partly because of sheer numbers - each additional infection is another opportunity for post-acute symptoms to develop or worsen.  The presentation of the Long COVID symptoms is not going to be consistent - patients may have good weeks and feel pretty close to normal, as well as bad weeks, where the symptoms are at their strongest.  Telling someone to "push through" on the assumption that it will just get better really isn't what helps the Long COVID patients.   "Long COVID is real. Patients deserve to be believed, and treatment should be individualized, rather than trying to fit or wait for a one-size-fits-all." —  Dr. Stephanie Grach   Connect with Dr. Stephanie Grach: Professional Bio: https://www.mayoclinic.org/biographies/grach-stephanie-l-m-d-m-s/bio-20536370  LinkedIn: https://www.linkedin.com/in/stephaniegrach    Connect with Therese: Website:  www.criticallyspeaking.net Bluesky: @CriticallySpeaking.bsky.social Instagram: @criticallyspeakingpodcast Email: theresemarkow@criticallyspeaking.net     Audio production by Turnkey Podcast Productions. You're the expert. Your podcast will prove it. 

Rochester is America's City for Health. It's the home of the world-famous Mayo Clinic. Listen to how the mayor of Rochester manages a city with this huge partner. And learn how to move with the mayor. Brought to you by The Good Government Institute, bringing together proven ideas, principled leaders, and real-world solutions to strengthen how we govern—not by reinventing the system, but by advancing what already works. GoodGovernmentShow.com Thanks to our sponsors: HelloNation Ourco Good News For Lefties (and America!) - Daily News for Democracy (Apple Podcasts | Spotify) How to Really Run a City Leading Iowa: Good Government in Iowa's Cities (Apple Podcasts | Spotify) The Context: A Podcast by the Charles F. Kettering Foundation The Good Government Show is part of The Democracy Group, a network of podcasts that examines what's broken in our democracy and how we can work together to fix it. The Royal Cousins: How Three Cousins Could Have Stopped A World War by Jim Ludlow Executive Producers: David Martin, David Snyder, Jim Ludlow Host/Reporter: David Martin Producers: David Martin, Jason Stershic Editor: Jason Stershic

Handheld Ultrasound and Detection of Valve and Other Structural Heart Disease   Guest: Jared Bird, M.D. Host: Paul Friedman, M.D.   Handheld ultrasound is rapidly changing cardiovascular structural heart disease assessment by allowing clinicians and researchers to detect valvular and structural heart disease earlier and more accurately. Advances in AI imaging guidance and interpretation further bridge the gap between physical exam and formal comprehensive echocardiography. It is important to realize how complimentary handheld ultrasound can be in the early detection of structural heat disease but does not replace diagnostic echocardiography.   Topics Discussed: How does handheld ultrasound improve upon the traditional physical exam when it comes to identifying valvular or structural heart disease? What are the most common valve or structural abnormalities that clinicians can reliably detect using handheld ultrasound today? How are we using handheld ultrasound to screen patients for structural heart disease in a research setting? How do AI-ECG and handheld ultrasound intersect to provide optimal screening of asymptomatic patients with structural heart disease?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode.   Podcast episode transcript found here.   Recorded on: 30-December-2025

What if you could detect Alzheimer's years before any symptoms appeared and stop it?Dr. Yogesh Shah is a Board-Certified Geriatrician and Mayo Clinic-trained memory specialist who has spent 25 years focused entirely on the early detection and prevention of dementia. In this episode, he makes a case that every entrepreneur in their 40s and 50s needs to hear: the window to protect your brain is now. Not at 70. Not after a diagnosis.America spends 20% of its GDP on healthcare, and nearly all of it goes to disease management. Dr. Shah explains why that approach is failing, what Mild Cognitive Impairment is and why it matters, and how a new FDA-approved blood test can identify Alzheimer's pathology years before any symptoms appear. He walks through the 14 lifestyle factors identified in the Lancet study that can reduce dementia risk by up to 45%, and explains how monoclonal antibody infusions are now removing amyloid plaque from the brains of patients caught early enough.What you will walk away with: an understanding of why 40 to 50% of dementia cases go undiagnosed and the real-world consequences, what the new p-tau blood tests are and how to ask your doctor about getting one, which lifestyle factors carry the most risk weight for entrepreneurs, and why managing your LDL, sleep, social connection, and chronic conditions in midlife is the most important thing you can do for your future brain health.Connect with Dr. Yogesh Shah on LinkedIn Hosted by John St. Pierre and Rich Hoffmann, Entrepreneurs United is built for founders and leaders who want straight talk on building businesses that actually work. New episodes every week.https://entrepreneursunited.us/links/

With Edoardo Conte and Daniele Andreini, Galeazzi-Sant'Ambrogio Hospital IRCCS, Milan - Italy and Gal Tsaban, Mayo Clinic, Rochester - USA. Link to paper Link to editorial

In this episode of the Chasing Giants Podcast, Don Higgins returns after spending time helping Robin recover from major surgery at Mayo Clinic. Don shares an emotional update on Robin's condition, the road ahead with chemo treatments, and thanks the Chasing Giants family for the overwhelming prayers and support. Terry also recaps an unforgettable Manitoba black bear hunt filled with giant bears, unbelievable footage, close encounters, and stories that will eventually become two full Chasing Giants TV episodes. The guys also dive into: Spring food plot challenges and excessive rain Soybean planting strategies and browse pressure The upcoming “Doubting Thomas” video release Why Scrape Magnet played a major role in Don's success Michigan becoming a one-buck state Supplemental feeding vs baiting Why mature bucks become nocturnal Sanctuary intrusion and fawn survival As always, the show blends faith, deer hunting, land management, and real-life perspective. Please continue praying for Robin and the Higgins family. Sponsors: Asio Gear – https://asiogear.com Real World Wildlife Products – https://realworldwildlifeproducts.com Hawke Optics – https://us.hawkeoptics.com Novix Outdoors – https://novixoutdoors.com Midwest Land Group – https://midwestlandgroup.com 360 Hunting Blinds – https://360huntingblinds.com Mike's Mighty Micros – https://mikesmightymicros.com Gingerich Tree Farm – https://gingerichtreefarm.com TagOut Technique – https://tagouttechnique.com Grubb Implement – https://grubbimplement.com Brenton USA – https://brentonusa.com Mathews Archery – https://mathewsinc.com Victory Auto Group – https://victorykc.com Wildlife Farming – https://wildlifefarming.com WiseEye Technologies – https://wiseeyetech.com DISCLAIMER: The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any sponsors or affiliated companies. © Chasing Giants. All rights reserved. This content may not be reproduced or distributed without written permission.

"When you have benign conditions, we're actually treating 3 gray, so a significant difference [versus doses of 60 gray for brain cancer]. Typically, when you treat at a high dose, the goal is to destroy tissue, like cancer tissue or cancer cells. But when we give a low dose, the goal is actually to modulate inflammation. And what it does is it slows down those inflammatory cells or those cells that release the chemicals that cause pain and inflammation," Amanda Meyer, DNP, APRN, CNP, family nurse practitioner in the Department of Radiation Oncology at the Mayo Clinic in Rochester, MN, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation therapy for noncancer indications. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 22, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge about the use of radiation to treat noncancerous conditions. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 365: Radiation-Associated Secondary Cancers Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices ONS Voice articles: Augmented Reality Simulations Reduce Patient Anxiety by Teaching Them About Radiation Therapy Highly Localized, Precision Radiation Therapies Require Nurses to Drive Care Coordination, Patient Education Quick Quiz: Test Your Knowledge of Radiation Care Coordination ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS Radiation Oncology Conference Recordings Bundle™ ONS ROCN™ Certification Review™ Radiation Oncology 101: 2024 ONS Bridge™ Session ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing articles: Findings From the 2023 Radiation Oncology Nursing Role Delineation Study to Shape the Future of the Subspecialty The Role of Advanced Practice Providers in Radiation Oncology in 2025 ONS Huddle Cards: Radiation Radiobiology German Society for Radiation Oncology (DEGRO): Guidelines in Radiotherapy: Radiotherapy for Benign Diseases To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We always typically think of it as cancer treatment, but we can use radiation for noncancerous conditions, as well. And radiation was actually used for benign diseases right after the discovery of x-rays. By the 1920s it was used a lot for different types of musculoskeletal, dermatologic issues, and different types of inflammatory conditions. And over time, since the 1920s, we've actually really gotten a really good understanding of it." TS 1:37 "When we're looking at what are good candidate characteristics, we do typically like older patients, so patients over the age of 65. And the rationale behind that is we know that there is a potential for a secondary risk of a skin cancer about 20 to 30 years after getting low-dose radiation, like a basal cell or squamous cell skin cancer. The older the patient is, the less likely they are to have any adverse effects from that." TS 8:22 "When we do the low-dose radiation, they've tried other measures that haven't been successful. However, we don't want a patient who is so severe that they're ready for surgery, when they're bone on bone, because we know that radiation isn't as effective when they are that severe. So there's this sweet window where low-dose radiation works best in these patients." TS 9:39 "When we're treating with a little bit higher dose for like a Dupuytren's or a Ledderhose, because it's an anti-proliferative dose, those patients, they do get more skin redness, more dry skin. That's very temporary, and it resolves within a week or two after treatment. But really, we don't see any acute side effects. The long-term side effect of the radiation-induced malignancy, again, is a very low—0.05% according to some of the European guidelines." TS 12:34 "I really wish people appreciated how interdisciplinary this is. We need to get referrals from family medicine and from primary care and internal medicine and pain medicine physicians and inflammatory physicians and podiatry and pain specialists. And we really need to use this multidisciplinary approach to get earlier referrals for patients because there is this sweet window of time where low-dose radiation works the best." TS 18:40

Darshan Shah, MD is a board-certified surgeon, published author, and Founder and CEO of Next Health – the first, largest and fastest-growing health optimization and longevity clinic. He earned his medical degree at the age of 21 from the University of Missouri-Kansas City, becoming one of the youngest doctors in the United States at the time. He continued his training at the Mayo Clinic and earned his MBA from Harvard Business School. As a longevity medicine specialist, he has advised thousands of patients on how to optimize their well-being and extend their healthspan and lifespan. Today on the show we discuss why living longer means nothing if your health span is broken, the biggest mistakes people make when chasing longevity, why most people should focus on metabolic health before biohacking, the blood markers Dr. Shah believes everyone should track, how strength training, walking, sleep, and nutrition protect your future, why ultra-processed foods are quietly wrecking your health, the truth about alcohol, weed, caffeine, fasting, sauna, cold plunge, red light therapy, wearables, supplements, NAD, and how toxins, stress, relationships, and circadian rhythm all impact how well you age. And much more.  Today's sponsor: Fatty15:  Get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/DOUG and using code DOUG at checkout Learn more about your ad choices. Visit megaphone.fm/adchoices

Host: Darryl S. Chutka, M.D  Guest: Mark D. Tyson, III, M.D., M.P.H.  Bladder cancer is one of the most common malignancies worldwide, and primary care clinicians are often the first to evaluate patients with bladder cancer. The symptoms are usually subtle and may include either gross or microscopic hematuria. The decision in whether to investigate these presenting symptoms can often impact early diagnosis and the patient's outcome. When should we investigate hematuria? What should an evaluation of hematuria consist of? What is the treatment for bladder cancer? How should patients with recurrent bladder cancer be managed? What role does the primary care clinician play in the long-term management of patients? I'll be asking these questions and more of my guest, Dr. Mark Tyson, a urologist at the Mayo Clinic as we discuss “Bladder Cancer”.  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

Host: Darryl S. Chutka, M.D.  Guest: Stacey Rizza, M.D.  Hantavirus has been in the news lately. Although it's rare, it can cause serious disease which can be life-threatening.  Early symptoms are similar to other common viral infections including fever, myalgias, headache, and fatigue. As a result, the ability to establish an early diagnosis is challenging. Who's at risk of acquiring Hantavirus? Does it have the potential to become our next pandemic? How likely is human-to-human transmission? Is there any effective treatment and what preventive measures should one take to minimize the acquisition of the disease? I'll get answers to these questions in this podcast as we discuss Hantavirus. My guest is an infectious disease specialist, Dr. Stacey Rizza from the Mayo Clinic.  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

In this episode, Raj, Ashwin, and Eddie sit down with Dr. Vincent Rajkumar — Professor of Medicine at Mayo Clinic and Chair of the ECOG Myeloma Committee — for a clinically focused conversation on newly diagnosed multiple myeloma. Topics span baseline workup, risk stratification, induction selection, transplant timing, MRD-directed decision-making, and maintenance strategy. The episode closes with a discussion of Open Medicine, a new medical education platform, and Dr. Rajkumar's ongoing advocacy on drug pricing reform.KEY TOPICS DISCUSSEDBaseline workup: 24-hour urine protein: It is important to obtain 24-hour urine protein with electrophoresis and immunofixation in all newly diagnosed patients — not for diagnosis, but to establish a baseline for long-term management and to distinguish M-protein from albuminuria. In patients where an FLC ratio ≥100 is the sole myeloma-defining criterion, a 24-hour urine Bence Jones protein ≥200 mg is part of the diagnostic threshold for treatment initiation. Myeloma cast nephropathy: when to biopsy: An involved FLC ≥50 mg/dL supports a presumptive diagnosis of cast nephropathy and treatment can begin without a kidney biopsy. Below this threshold — particularly if renal involvement is the sole myeloma-defining event — kidney biopsy is warranted to exclude light chain deposition disease, MPGN, or other unrelated disorders. It warrants aggressive early treatment (Dara-VCD or Dara-VD), starting even before bone marrow results are available when the diagnosis is clinically clear.Solitary plasmacytoma [with or without minimal bone marrow involvement]: Patients with ~10% clonal plasma cells technically meet criteria for myeloma, but management in this borderline zone warrants shared decision-making. Solitary plasmacytoma as sitting between smoldering myeloma and overt myeloma on the disease spectrum. Risk stratification: revised IMWG criteria: The new revision aimed to keep the high-risk designation to ≤15–20% of patients. Del 17p alone confers high-risk status. TP53 mutation without del 17p is exceedingly rare and FISH alone captures the vast majority of cases. All other cytogenetic abnormalities (t(4;14), t(14;16), t(14;20), 1q gain, 1p deletion, biallelic 1p) require at least one co-occurring abnormality to define high risk. Elevated β2-microglobulin with normal renal function is retained as a proxy for high tumor burden. Emergent indications for treatment initiation: The three situations warranting urgent treatment are acute cast nephropathy (days matter for renal recovery), cord compression (surgery vs. radiation vs. systemic therapy determined by acuity), and hypercalcemia. Induction regimen selection: For fit, transplant-eligible patients, the preferred induction is a quadruplet — Dara-VRd or Isa-VRd — with dose adjustment as needed. Triplets (Dara-Rd or Isa-Rd) are reserved for those unable to tolerate a quadruplet even with dose reduction. Carfilzomib-based induction is not favored: head-to-head data show no benefit of KRd over VRd in NDMM, and the cost differential is substantial. Lenalidomide dosing: Starting dose should be individualized: 15 mg for patients over 75, those with small body habitus (

What if the biggest threat to your success in medical training has nothing to do with how much you study? Vance Lehman, professor of neuroradiology and chief of neuroradiology education at the Mayo Clinic, spent over two years researching why capable trainees stumble despite strong clinical knowledge. In this episode, based on his KevinMD article "The hidden curriculum: What medical school does not teach you," he explains how unspoken expectations, invisible social dynamics, and stealth influences shape evaluations and career trajectories far more than most trainees realize. You will learn why making a strong first impression on a new rotation triggers a powerful psychological feedback loop, how generational biases from attendings quietly distort trainee evaluations, and why years of excelling at test scores can actually leave you blind to the skills that matter most in clinical settings. Lehman also shares practical steps any medical student or resident can take tomorrow to stop leaving their reputation to chance. If you are in medical training or teach those who are, this episode reveals the forces you feel every day but have never had a name for. Tune into our episode "2026 Cholesterol Guidelines: LDL goals, lipoprotein(a), and coronary calcium scoring," brought to you by Novartis Pharmaceuticals Corporation. For the first time in eight years, LDL cholesterol goals have changed, and preventive cardiologist Seth Baum says the new guidelines are a long-overdue course correction. He breaks down the new LDL targets for your highest-risk patients, why the LDL hypothesis should be retired in favor of the LDL fact, why lipoprotein(a) screening finally belongs in every patient's workup, what a coronary calcium score over 300 really means for how aggressively you treat, and how to talk to statin-skeptical patients without losing their trust. Listen now at KevinMD.com/cholesterol. VISIT SPONSOR → https://kevinmd.com/cholesterol Partner with me on the KevinMD platform. With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Whether you need a sponsored article, email campaign, video interview, or a spot right here on the podcast, I offer the trusted space your brand deserves to be heard. Let's work together to tell your story. PARTNER WITH KEVINMD → https://kevinmd.com/influencer SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended